Alcoholic Liver Disease
Alcoholic liver disease is a spectrum of hepatic injury caused by chronic excessive alcohol consumption, ranging from fatty liver (steatosis) to alcoholic hepatitis and ultimately cirrhosis.
Alcoholic Liver Disease (ALD)
Alcoholic liver disease (ALD) encompasses a spectrum of hepatic pathology caused by chronic and/or excessive alcohol consumption. It ranges from simple steatosis (fatty liver) through alcoholic steatohepatitis (ASH) to established cirrhosis and its complications. The term captures the progressive damage ethanol and its metabolites inflict on hepatocytes, stellate cells, and the hepatic microenvironment.
Breaking down the name: "Alcoholic" = caused by ethanol; "Liver Disease" = pathology of the liver. The spectrum parallels its non-alcoholic counterpart (MASLD/NAFLD), but the causative insult is ethanol rather than metabolic dysfunction — though in clinical practice, these frequently coexist.
The natural history and classification of ALD describes a wide clinical spectrum ranging from mild LFT abnormalities to cirrhosis, mainly divided into: Alcoholic fatty liver disease (AFLD), Alcoholic steatohepatitis, and Alcoholic cirrhosis — which often overlap considerably. [1][2]
Key Concept: Spectrum, Not a Single Disease
ALD is not one disease but a continuum. A patient can have features of more than one stage simultaneously (e.g., steatosis + steatohepatitis, or steatohepatitis superimposed on established cirrhosis). Think of it as a "layer cake" of pathology.
2. Epidemiology
- Alcohol-related liver disease accounts for approximately 50% of all cirrhosis-related deaths worldwide [3].
- The WHO estimates that harmful alcohol use contributes to > 3 million deaths annually; liver disease is the leading cause of alcohol-attributable mortality.
- ALD is the most common cause of cirrhosis in Western countries (Europe, North America, Australia).
- In Hong Kong, HBV is by far the most common cause of cirrhosis (~64–75% by WHO pooled estimates and local expert opinion), with HCV closer to 5–10%, and alcohol/drinking probably > 5%. [4]
- However, ALD prevalence is rising in HK due to changing social habits, increased per-capita alcohol consumption, and Westernization of lifestyle.
- The concept of concomitant liver disease is important: many patients with HBV overlap and also possess MAFLD [4]. Similarly, a patient labelled as "alcoholic hepatitis" may also have chronic HBV — anyone presenting with chronic liver disease and a history of alcoholism must have other causes excluded [5].
- Alcoholic liver disease accounts for ~4% of cirrhosis in HK [6].
- Women are more susceptible to alcohol-related liver injury than men at lower cumulative doses. This is due to:
- Lower gastric alcohol dehydrogenase (ADH) activity → higher effective blood alcohol level per unit consumed.
- Higher body fat percentage → lower volume of distribution for ethanol.
- Estrogen increases gut permeability → enhanced endotoxin translocation → greater Kupffer cell activation.
- Threshold for ALD: typically > 40 g/day in men and > 20 g/day in women over a prolonged period, though individual susceptibility varies enormously.
One standard drink ≈ 10 g pure ethanol (HK/Australian standard) ≈ a 330 mL can of beer (5%), 100 mL wine (12%), or 30 mL spirits (40%).
Prolonged heavy drinking (> 50–60 g/day) is associated with alcoholic hepatitis; the patient may cut down recently due to symptoms. [7]
Not all heavy drinkers develop ALD — only about 10–20% of chronic heavy drinkers develop cirrhosis. This tells you that alcohol alone is necessary but not sufficient; additional cofactors modulate risk.
| Risk Factor | Mechanism / Explanation |
|---|---|
| Quantity & duration of alcohol | Dose-dependent hepatotoxicity; average consumption of 160 g/d for > 8 years is a classic threshold for cirrhosis [2] |
| Pattern of drinking | Binge drinking and daily drinking are worse than intermittent; drinking outside meals increases risk (food slows gastric emptying → lower peak BAL) |
| Female sex | Lower ADH, higher body fat, estrogen-mediated gut permeability (see above) |
| Genetic factors | Polymorphisms in ADH, ALDH (e.g., ALDH2*2 common in East Asians — causes "Asian flush"); PNPLA3 I148M variant increases steatosis and fibrosis risk |
| Concomitant viral hepatitis | HBV and HCV synergistically accelerate fibrosis [5][6]; HCV is particularly synergistic with alcohol — even moderate drinking accelerates HCV-related cirrhosis |
| Obesity / Metabolic syndrome | Additive or synergistic steatosis; shared pathways of lipotoxicity, insulin resistance, and oxidative stress |
| Nutritional deficiency | Protein-calorie malnutrition, folate and B-vitamin deficiency impair hepatocyte regeneration and antioxidant defences |
| Smoking | Increases oxidative stress, accelerates fibrosis |
| Iron overload | Catalyzes free radical formation (Fenton reaction), worsens oxidative hepatocyte injury |
| Drugs | Paracetamol (depletes glutathione already reduced by ethanol), methotrexate, isoniazid — compounding hepatotoxicity |
ALDH2*2 and the "Asian Flush"
The ALDH2*2 allele (prevalent in ~30–40% of East Asians, including Hong Kong Chinese) causes accumulation of acetaldehyde after drinking, resulting in facial flushing, tachycardia, and nausea. Paradoxically, this allele is protective against ALD because it discourages heavy drinking. However, individuals who drink despite the flush face higher acetaldehyde exposure and increased risk of oesophageal squamous cell carcinoma.
4. Anatomy and Function of the Liver (Relevant to ALD)
Understanding ALD requires appreciating the liver's microarchitecture, because ethanol damage is zonally distributed.
- The liver is organised into hexagonal lobules centred on a central vein (terminal hepatic venule), with portal triads at the periphery.
- Rappaport's acinus divides the parenchyma into three zones based on proximity to the portal triad (oxygen-rich blood source):
- Zone 1 (periportal): Closest to portal triad; highest O₂, receives blood first; site of gluconeogenesis, β-oxidation, urea synthesis.
- Zone 2 (mid-zone): Intermediate.
- Zone 3 (pericentral/centrilobular): Closest to central vein; lowest O₂; site of lipogenesis, drug metabolism (CYP450), ketogenesis.
Why does this matter for ALD? Alcohol is primarily metabolised in Zone 3 hepatocytes, which are richest in CYP2E1. This is why alcoholic liver injury (steatosis, steatohepatitis, fibrosis) characteristically begins in the centrilobular/perivenular (Zone 3) region, producing pericellular and perivenular fibrosis — a hallmark histological pattern.
| Cell Type | Role in ALD |
|---|---|
| Hepatocytes | Primary site of ethanol metabolism; undergo steatosis, ballooning, necrosis |
| Kupffer cells (resident macrophages) | Activated by endotoxin (LPS) translocated from gut → release TNF-α, IL-1, IL-6 → drive inflammation |
| Hepatic stellate cells (HSCs) | Normally quiescent, store vitamin A; activated by oxidative stress and cytokines → transform into myofibroblasts → produce collagen → fibrosis |
| Sinusoidal endothelial cells | Lose fenestrations ("capillarisation of sinusoids") → impaired exchange between blood and hepatocytes |
- The liver has a dual blood supply: ~75% from portal vein (nutrient-rich, oxygen-poor) and ~25% from hepatic artery (oxygen-rich).
- Portal hypertension develops when fibrosis distorts sinusoidal architecture, increasing intrahepatic resistance → this drives many complications (ascites, varices, splenomegaly).
5. Etiology (with Hong Kong Focus) and Respective Pathophysiology
5.1 Ethanol Metabolism — The Root of All Evil
Ethanol is metabolised through three principal pathways, all occurring predominantly in the liver:
- Location: Cytosol of hepatocytes.
- Reaction: Ethanol + NAD⁺ → Acetaldehyde + NADH + H⁺.
- Rate-limiting factor: Availability of NAD⁺ — this is critical because chronic alcohol use creates a massive NADH/NAD⁺ imbalance (redox shift).
- Location: Smooth endoplasmic reticulum (ER), predominantly Zone 3 hepatocytes.
- Reaction: Ethanol + NADPH + O₂ → Acetaldehyde + NADP⁺ + H₂O.
- Key point: CYP2E1 is inducible — chronic heavy drinking upregulates CYP2E1 by 5–10-fold. This is why chronic drinkers develop metabolic tolerance (can handle more alcohol before feeling drunk) but also produce more reactive oxygen species (ROS) as a by-product.
- CYP2E1 induction also increases activation of other hepatotoxins (e.g., paracetamol → NAPQI) → explains why alcoholics are at higher risk of paracetamol toxicity.
- Peroxisomal; quantitatively minor except perhaps in the brain.
- Acetaldehyde is oxidised by aldehyde dehydrogenase 2 (ALDH2) in mitochondria.
- ALDH2*2 variant (common in HK/East Asian populations) has markedly reduced activity → acetaldehyde accumulates → "Asian flush" syndrome.
- Acetaldehyde is directly toxic: forms protein adducts, damages mitochondria, triggers immune responses.
5.2 Pathophysiological Mechanisms of Alcohol-Induced Liver Injury
The damage from ethanol is not a single hit but a multi-hit process:
- Both ADH and ALDH reactions consume NAD⁺ and generate NADH.
- Excess NADH:
- Inhibits fatty acid β-oxidation (which requires NAD⁺) → fat accumulates in hepatocytes → steatosis.
- Inhibits gluconeogenesis → hypoglycaemia (especially in fasting alcoholics).
- Promotes lactate production (pyruvate + NADH → lactate) → lactic acidosis.
- Inhibits the TCA cycle (which requires NAD⁺) → acetyl-CoA diverted to fatty acid synthesis.
Think of it this way: the liver is so busy oxidising ethanol that it "uses up" all its NAD⁺. Without NAD⁺, it can't burn fat, can't make glucose, and shunts everything into fat storage. This is why even a short binge can cause fatty liver.
- Protein adducts: Acetaldehyde binds covalently to proteins (tubulin, mitochondrial proteins, collagen) → disrupts cytoskeletal function, impairs mitochondrial respiration, triggers neoantigen formation → immune-mediated hepatocyte injury.
- Mitochondrial damage: Swollen, dysfunctional mitochondria → impaired oxidative phosphorylation → more ROS.
- Collagen synthesis: Directly stimulates hepatic stellate cells to produce collagen → fibrosis.
- CYP2E1 metabolism generates abundant ROS (superoxide, hydroxyl radicals, hydrogen peroxide).
- ROS cause lipid peroxidation of hepatocyte membranes → cell death, release of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) → further stellate cell activation.
- Simultaneously, ethanol depletes glutathione (the liver's main antioxidant) → hepatocytes become defenceless.
- Chronic ethanol:
- Increases intestinal permeability ("leaky gut") by disrupting tight junctions.
- Causes gut dysbiosis (bacterial overgrowth, shift toward Gram-negative organisms).
- Result: Endotoxin (lipopolysaccharide/LPS) from Gram-negative bacteria translocates via the portal vein to the liver.
- LPS binds TLR4 (Toll-like receptor 4) on Kupffer cells → activates NF-κB → massive release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) → neutrophilic inflammation (a hallmark of alcoholic hepatitis).
- TNF-α also directly induces hepatocyte apoptosis and necrosis.
- Acetaldehyde-protein adducts and oxidised lipid adducts act as neoantigens.
- Both innate (neutrophils, Kupffer cells) and adaptive (T-cells, antibodies) immune responses are activated against modified hepatocyte proteins → chronic inflammation.
- This partially explains why some patients' liver disease continues to progress even after cessation of drinking ("immune momentum").
- Activated hepatic stellate cells (HSCs) are the central effector of fibrosis.
- Triggers for HSC activation: acetaldehyde, ROS, lipid peroxidation products, TGF-β (from Kupffer cells), PDGF.
- HSCs transform into myofibroblasts → deposit collagen I and III in the space of Disse → pericellular and perivenular fibrosis (chicken-wire pattern) → if sustained, progresses to bridging fibrosis → cirrhosis with regenerative nodules.
- Ethanol inhibits hepatocyte proliferation and promotes apoptosis.
- Nutritional deficiencies (folate, S-adenosylmethionine, zinc) impair DNA synthesis and antioxidant capacity → hepatocytes cannot effectively regenerate to replace dead cells.
Why does AST > ALT in Alcoholic Liver Disease?
In alcoholic hepatitis, AST > ALT with a ratio ≥ 1.5–2:1. [7][8][9] This is one of the most commonly tested points. The reasons:
- Pyridoxal-5-phosphate (P5P) deficiency: ALT synthesis requires pyridoxal-5-phosphate (the active form of vitamin B6) as a cofactor more than AST does. Chronic alcoholics are commonly B6-deficient → disproportionate reduction in serum ALT → ratio tips toward AST.
- Mitochondrial AST (mAST) release: Alcohol causes mitochondrial damage → releases the mitochondrial isoenzyme of AST into the blood, boosting total AST.
- Serum AST almost never > 500 U/L (and classically < 300 U/L) in alcoholic hepatitis [8][9] — this distinguishes it from viral hepatitis or ischaemic hepatitis, where transaminases can reach thousands.
6. Classification
ALD is classified along its histopathological and clinical spectrum:
| Stage | Key Histological Features | Reversibility |
|---|---|---|
| 1. Alcoholic Fatty Liver (Steatosis) | Macrovesicular steatosis (large fat droplets displacing nucleus), predominantly Zone 3; no significant inflammation or fibrosis | Fully reversible with abstinence (within 2 weeks to 3 months) [2] |
| 2. Alcoholic Steatohepatitis (ASH) | Steatosis + hepatocyte ballooning + lobular neutrophilic infiltrate + Mallory-Denk bodies (damaged cytokeratin intermediate filaments) + pericellular/perivenular fibrosis ("chicken-wire" pattern) | Partially reversible; fibrosis may persist |
| 3. Alcoholic Fibrosis | Progressive collagen deposition; perisinusoidal and perivenular initially → bridging fibrosis | May stabilise or regress with abstinence (early stages) |
| 4. Alcoholic Cirrhosis | Diffuse nodular regeneration surrounded by fibrous septa; distortion of architecture; initially micronodular (< 3 mm nodules — Laennec cirrhosis) → may become macronodular over time | Irreversible in advanced stages [6] |
Alcoholic fatty liver develops within 2 weeks of regular alcohol ingestion and resolves rapidly (≤ 3 months) with abstinence. [2] 8–20% lifetime risk of progressing into cirrhosis, especially if liver biopsy shows marked fatty infiltration, Mallory bodies, or pericellular/perivenular fibrosis. [2]
- Alcoholic Fatty Liver Disease (AFLD) — Usually asymptomatic, incidental finding.
- Alcoholic Hepatitis (AH) — An acute clinical syndrome; may occur de novo or superimposed on pre-existing cirrhosis; has its own prognostic scoring.
- Alcoholic Cirrhosis — The end-stage; presents with decompensation (ascites, variceal bleed, encephalopathy, jaundice).
These overlap considerably [2] — a patient with alcoholic hepatitis may already have underlying cirrhosis, and the acute hepatitis episode may be the precipitant for decompensation.
Several scores predict prognosis in acute alcoholic hepatitis:
| Score | Parameters | Interpretation |
|---|---|---|
| Maddrey Discriminant Function (mDF) | 4.6 × (PT patient − PT control) + Total bilirubin (mg/dL) | ≥ 32 = severe AH; indication for corticosteroids |
| MELD score | Bilirubin, INR, Creatinine | ≥ 21 = high 90-day mortality; also used for transplant prioritisation |
| Lille score | Change in bilirubin at day 7 of steroid therapy + age, albumin, creatinine, PT | > 0.45 at day 7 = steroid non-responder → consider stopping steroids |
| Glasgow Alcoholic Hepatitis Score (GAHS) | Age, WCC, urea, INR, bilirubin | ≥ 9 = poor prognosis |
Child-Pugh score (5 parameters: albumin, bilirubin, INR/PT, ascites, encephalopathy) and MELD score (3 parameters: bilirubin, INR, creatinine) are used for cirrhosis staging. MELD is used for transplantation priority — in HK, it is not first come first served. [5]
7. Clinical Features
The clinical features of ALD depend on which stage the patient is at. Remember the overlap: a patient may have features of more than one stage simultaneously.
7.1 Alcoholic Fatty Liver Disease (AFLD)
Typically asymptomatic [10]
- Vague right upper quadrant discomfort or fullness — due to hepatic capsular distension from fat-laden, swollen hepatocytes expanding the liver parenchyma. (The liver parenchyma itself has no pain fibres; only the Glisson's capsule is innervated.)
- Nausea and vomiting — due to direct gastric irritant effect of alcohol + mild hepatic dysfunction.
- Fatigue / malaise — non-specific; due to altered hepatic metabolism and nutritional deficiency.
- Normal liver size or hepatomegaly [10] — the liver may be palpably enlarged, smooth, and non-tender. Fat accumulation within hepatocytes physically expands liver volume.
- Jaundice — mild or absent [10]; occurs only if steatosis is severe enough to compress intrahepatic bile canaliculi or if there is early concomitant hepatitis.
- No stigmata of chronic liver disease at this stage (no spider naevi, palmar erythema, etc.).
7.2 Alcoholic Hepatitis (AH)
This is the clinically dramatic form. It represents an acute inflammatory injury superimposed on chronic alcohol use, and can range from mild (asymptomatic LFT derangement) to life-threatening (multi-organ failure).
-
Jaundice [7][10] — the hallmark. Often rapid-onset and deep. Due to:
- Hepatocyte necrosis → impaired bilirubin conjugation and excretion.
- Intrahepatic cholestasis from swollen hepatocytes and inflammatory infiltrate compressing bile canaliculi.
- +/- hemolysis (Zieve's syndrome) [7] — the combination of jaundice, hyperlipidaemia, and haemolytic anaemia in alcoholic hepatitis; haemolysis contributes unconjugated bilirubin.
-
Abdominal pain/discomfort [7][10] — typically right upper quadrant, dull aching; due to hepatic capsular distension from inflamed, swollen liver. "Liver parenchyma has no nerve fibres → only when you have inflammation and swelling of the liver, you will get dull aching." [11]
-
Low-grade fever [7][10] — due to:
- Cytokine release (TNF-α, IL-6) from activated Kupffer cells → systemic inflammatory response.
- Must differentiate from infection (SBP, pneumonia, UTI) — alcoholic hepatitis patients are immunocompromised.
-
Anorexia, nausea, vomiting [10] — direct toxic effect on GI mucosa + hepatic dysfunction + associated malnutrition.
-
Muscle weakness [10] — due to sarcopenia from protein-calorie malnutrition, direct myotoxicity of ethanol, and hypokalaemia.
-
Recent reduction in alcohol intake — the patient may have cut down recently due to symptoms [7]. This is a classic history point: the onset of symptoms often prompts the patient to reduce or stop drinking, so don't be fooled into thinking "they weren't drinking much."
-
Hepatomegaly [10][12] — alcoholic hepatitis is a known cause of hepatomegaly, usually a mild, soft hepatomegaly [12]. The liver is enlarged, smooth, and tender on palpation (unlike the non-tender fatty liver). Tenderness is due to acute inflammation of the parenchyma causing capsular distension.
-
Jaundice (visible when total bilirubin > 34 μmol/L; inspect sclera, sublingual mucosa, palms).
-
Features of portal hypertension (can develop in the absence of cirrhosis!) [10]:
-
Enlarged parotid gland [12] — a classic sign of chronic alcoholism (not specific to AH); thought to be due to autonomic neuropathy causing salivary gland hypertrophy, or direct toxic effect of ethanol on parotid tissue.
-
Dupuytren's contracture — thickening of palmar fascia, more common in chronic alcoholics; mechanism not fully understood but related to fibroblast activation.
-
Proximal muscle wasting / sarcopenia — due to malnutrition, direct myotoxicity.
-
Signs of nutritional deficiency:
- Angular stomatitis, glossitis (B-vitamin deficiency)
- Peripheral neuropathy (thiamine/B1 and B12 deficiency)
- Bruising (vitamin K deficiency — fat-soluble vitamin malabsorption + impaired hepatic synthesis of clotting factors)
Zieve's Syndrome
+/- haemolysis (Zieve's syndrome) [7] — described in 1958 by Leslie Zieve. The triad is: jaundice + hyperlipidaemia + haemolytic anaemia in a patient with alcoholic hepatitis. The haemolysis is thought to be due to alcohol-induced alteration of red cell membrane lipid composition, making them rigid and susceptible to splenic sequestration. Hyperlipidaemia occurs because ethanol inhibits lipoprotein lipase and promotes hepatic lipogenesis. This is a rare but classic exam association.
7.3 Alcoholic Cirrhosis
-
Constitutional symptoms: anorexia, weight loss, fatigue, muscle weakness, muscle cramps [10] — chronic catabolism, sarcopenia, electrolyte disturbances (hypokalaemia, hypomagnesaemia).
-
Jaundice [10] — progressive as synthetic and excretory function deteriorates.
-
Abdominal distension — due to ascites (see pathophysiology below).
-
Easy bruising/bleeding — due to impaired synthesis of clotting factors (II, VII, IX, X — all vitamin K-dependent, made in liver) and thrombocytopenia (splenic sequestration from portal hypertension).
-
Peripheral oedema — due to hypoalbuminaemia (↓oncotic pressure) + portal hypertension + secondary hyperaldosteronism.
-
Features of portal hypertension: ascites and oedema, variceal bleeding, hepatic encephalopathy [10].
Signs
Stigmata of chronic liver disease are more common in alcoholic cirrhosis than cirrhosis of other causes [2]. This is because ethanol has direct vasodilatory and hyperestrogenic effects beyond what other aetiologies produce.
| Sign | Pathophysiological Basis |
|---|---|
| Spider naevi (> 5 abnormal) | Arteriolar vasodilatation due to hyperestrogenism (impaired hepatic oestrogen metabolism) + increased angiogenic factors (e.g., VEGF). Distributed in the territory of the SVC (face, neck, upper chest, arms). Blanch centrally on pressure; re-fill from centre outward. |
| Palmar erythema | Hyperdynamic circulation + hyperestrogenism → arteriolar vasodilatation in thenar and hypothenar eminences. |
| Gynaecomastia | Hyperestrogenism — impaired hepatic clearance of oestrogens; also alcohol directly inhibits testicular function → ↓testosterone. |
| Testicular atrophy | Direct ethanol toxicity to Leydig cells + hyperestrogenism → hypogonadism. |
| Loss of male-pattern hair | Hyperestrogenism + ↓testosterone. |
| Jaundice | Impaired bilirubin conjugation and excretion. |
| Ascites | Portal hypertension + hypoalbuminaemia + splanchnic vasodilatation → effective hypovolaemia → RAAS and ADH activation → sodium and water retention. |
| Caput medusae | Recanalisation of paraumbilical veins due to portal hypertension; blood shunts from portal to systemic circulation via periumbilical veins. |
| Splenomegaly | Congestive enlargement due to portal hypertension (back-pressure in splenic vein). |
| Asterixis (liver flap) | Negative myoclonus due to hepatic encephalopathy — accumulation of neurotoxins (ammonia, manganese) impairs neuromuscular junction function. |
| Fetor hepaticus | Sweet, musty breath odour due to dimethyl sulphide (mercaptans) normally cleared by liver. |
| Leukonychia (white nails) | Hypoalbuminaemia → altered nail bed protein composition. |
| Terry's nails | White nail bed with distal pink band — due to hypoalbuminaemia. |
| Muehrcke's lines | Paired white transverse bands; due to hypoalbuminaemia (resolve when albumin normalises). |
| Clubbing | Mechanism unclear; possibly related to hepatopulmonary syndrome (intrapulmonary shunting). |
| Dupuytren's contracture | Palmar fascial fibrosis — common in chronic alcoholics (see above). |
| Parotid enlargement | Chronic alcohol effect (see above). |
- Liver size may be normal, small, or enlarged [10] — In alcoholic cirrhosis, the liver may be small (end-stage, shrunken, fibrotic) or enlarged (if active steatohepatitis or fatty infiltration coexists).
- Peripheral oedema — hypoalbuminaemia + sodium retention.
- Ascites — shifting dullness, fluid thrill on examination.
Other features of chronic alcohol misuse: cardiomyopathy, neuropathy, pancreatitis [2]:
| Sign/Condition | Mechanism |
|---|---|
| Peripheral neuropathy | Thiamine (B1) deficiency → Wallerian degeneration of peripheral nerves; also direct ethanol neurotoxicity. Presents as stocking-glove sensory loss, painful paraesthesia. |
| Wernicke's encephalopathy | Thiamine deficiency → haemorrhagic necrosis of mamillary bodies and periaqueductal grey matter. Triad: confusion, ophthalmoplegia, ataxia. |
| Korsakoff's syndrome | If Wernicke's untreated → anterograde amnesia, confabulation. |
| Alcoholic cardiomyopathy | Direct ethanol toxicity to cardiomyocytes → dilated cardiomyopathy with ↓EF [13]. |
| Chronic pancreatitis | Alcoholic is the major aetiology of chronic pancreatitis [14]; calcifying type with intraductal stones. |
| Macrocytosis (↑MCV) | Increase in MCV → toxic alcohol can permeate the cell membrane of RBCs and alter lipid structures of the membrane [8][9]; also folate deficiency. |
| Proximal myopathy | Direct ethanol myotoxicity → type II fibre atrophy. |
| Cerebellar degeneration | Anterior vermis atrophy → broad-based gait, truncal ataxia. |
In alcoholic hepatitis: [7][8][9]
| Parameter | Expected Finding | Why |
|---|---|---|
| AST:ALT ratio | ≥ 1.5:1 (classically ≥ 2:1) | B6 deficiency → ↓ALT; mitochondrial damage → ↑mAST |
| AST level | Seldom > 400–500 U/L | Moderate hepatocyte injury; if AST > 500, think of other/concomitant causes |
| GGT | Markedly elevated | GGT is an inducible enzyme; alcohol is a potent inducer. Isolated rise in GGT with relatively normal ALP → think alcohol [5][8] |
| MCV | Elevated (macrocytosis) | Direct membrane toxicity + folate deficiency [8][9] |
| Bilirubin | Elevated (conjugated predominant) | Hepatocyte dysfunction + intrahepatic cholestasis |
| INR / PT | Prolonged | Impaired synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) |
| Albumin | Low | Impaired hepatic synthetic function |
| Platelets | Low | Hypersplenism (portal hypertension), direct marrow suppression by ethanol |
| WBC | Elevated (neutrophilia) | Inflammatory response; TNF-α, IL-8 drive neutrophil recruitment |
| IgA | Elevated | Chronic antigenic stimulation via gut-liver axis |
| Triglycerides | Elevated | Impaired VLDL secretion, ↑hepatic lipogenesis |
May have hepatic decompensation (↑INR, Bilirubin) [7]
High Yield: The 4 Exceptions Where AST > ALT
In usual circumstances, ALT level > AST level in diseases primarily affecting the liver, EXCEPT: [8][9]
- Alcoholic hepatitis (AST > ALT, ratio > 2:1) — AST seldom > 500 U/L; check GGT, MCV
- Hepatocellular carcinoma — check viral markers, AFP, imaging
- Congestive heart failure — check clinical context, US liver (enlarged liver, engorged hepatic vein)
- Ischaemic hepatitis — check clinical context (profound shock); disproportionate increase in LDH
This is a favourite exam question.
Assessment of liver steatosis requires: [15]
- Detailed drinking history
- Cardiometabolic risk factors
- Drugs (corticosteroids / tamoxifen / valproate / methotrexate etc.)
- Concomitant liver disease
- Others (hypothyroid / PCOS / panhypopituitarism / bypass surgery / genetic)
- LFTs (ALT / AST)
- Platelet count! (to be explained later — low platelets suggest advanced fibrosis/portal hypertension)
Platelet Count as a Fibrosis Marker
A falling platelet count in a patient with chronic liver disease is an ominous sign — it suggests progressive portal hypertension with splenic sequestration (hypersplenism) and/or decreased hepatic thrombopoietin production. This is the basis for non-invasive fibrosis scores like FIB-4 (which includes platelet count) and is why platelet count is highlighted as important in the assessment of liver steatosis [15].
On abdominal examination of a patient with suspected ALD: [16]
- Inspection: Jaundice, spider naevi (upper body), gynaecomastia, caput medusae, abdominal distension, muscle wasting.
- Palpation: Hepatomegaly (assess size, consistency, tenderness, surface — smooth vs nodular, edge), splenomegaly (Traube's space dull), ascites (shifting dullness, fluid thrill).
- Percussion: Liver span (normal 6–12 cm in MCL), shifting dullness.
- Auscultation: Hepatic bruit (HCC?), venous hum over caput medusae.
Also look for enlarged parotid gland, Dupuytren's contracture, peripheral neuropathy, and proximal myopathy — signs of chronic alcohol misuse.
The lecture slides emphasise that fatty liver is classified into: Alcoholic fatty liver and NASH/MAFLD. [17]
| Feature | ALD | MASLD (formerly NAFLD) |
|---|---|---|
| Cause | Ethanol > 20–40 g/day | Metabolic risk factors (obesity, T2DM, dyslipidaemia) |
| AST:ALT ratio | > 2:1 | Usually < 1 (ALT > AST) |
| GGT | Disproportionately elevated | Mildly elevated |
| MCV | Elevated | Normal |
| Histology | Zone 3 steatosis, neutrophilic infiltrate, Mallory-Denk bodies, perivenular fibrosis | Zone 3 steatosis, lobular inflammation (mixed), ballooning, perisinusoidal fibrosis |
| Response to abstinence | Steatosis resolves | N/A (requires weight loss/metabolic control) |
In HK, many patients have BOTH — concomitant ALD and MASLD, or HBV + MASLD. This "dual liver disease" concept is increasingly recognised and affects management strategy. [4][17]
Must exclude: [7]
- Biliary obstruction (imaging)
- Other types of hepatitis (viral, drug-induced, autoimmune)
This is critical: anyone presenting with chronic liver disease and a history of alcoholism must exclude other causes [5]:
- Check viral hepatitis markers (HBsAg, anti-HCV)
- Check autoimmune markers (ANA, ASMA, anti-LKM)
- Check drug/toxin exposure
- Check metabolic causes (ferritin/transferrin saturation for haemochromatosis, ceruloplasmin for Wilson's)
Don't Get Fooled
"Don't get fooled with alcoholic hepatitis — find out other things if possible." [5] A classic exam and clinical pitfall is attributing everything to alcohol when the patient actually has concomitant HBV, HCV, or autoimmune hepatitis. One patient in the teaching clinic case actually had a positive HCV alongside their alcoholic liver disease [5].
Apart from CAD, other cardiovascular conditions associated with high alcohol content include: [18]
- Coronary artery disease
- Atrial fibrillation → cardiac arrhythmias
- Alcoholic dilated cardiomyopathy (ACM)
- Hypertension
Alcohol and the brain — from psychiatric to neuropsychiatric perspectives: [19]
- Alcohol use disorder, dependence, withdrawal (seizures, delirium tremens)
- Wernicke-Korsakoff syndrome
- Cerebellar degeneration
- Alcoholic dementia
- Peripheral neuropathy
- Central pontine myelinolysis (if sodium corrected too rapidly during management)
Drug-induced hepatic injury, including alcohol, TCM/herbal tea is listed as a cause of hepatitis flare-up in chronic HBV patients [20].
| Feature | Fatty Liver | Alcoholic Hepatitis | Alcoholic Cirrhosis |
|---|---|---|---|
| Symptoms | Usually none; vague RUQ discomfort | Jaundice, fever, RUQ pain, anorexia, N/V | Constitutional (LOW, LOA, fatigue), ascites, bleeding |
| Liver size | Normal or enlarged | Enlarged, tender | Normal, small, or enlarged |
| Stigmata of CLD | Absent | May be present | Prominent |
| Portal HTN features | Absent | Can occur even WITHOUT cirrhosis | Present |
| Lab: AST:ALT | Mildly elevated, ALT ≥ AST | ≥ 1.5–2:1, AST < 400–500 | Variable, often AST > ALT |
| Lab: GGT | Elevated | Markedly elevated | Elevated |
| Lab: Bilirubin | Normal or mildly elevated | Elevated | Elevated |
| Lab: INR | Normal | May be prolonged (severity marker) | Prolonged |
| Lab: Albumin | Normal | May be low | Low |
| Reversibility | Fully reversible | Partially reversible | Irreversible (advanced) |
High Yield Summary
-
ALD is a spectrum: Steatosis → Steatohepatitis → Fibrosis → Cirrhosis, with frequent overlap between stages.
-
Pathophysiology is multi-hit: NADH/NAD⁺ imbalance (→ steatosis), acetaldehyde toxicity (→ protein adducts, mitochondrial damage), CYP2E1-generated ROS (→ oxidative stress), gut-liver axis endotoxin (→ Kupffer cell activation, TNF-α), and stellate cell activation (→ fibrosis).
-
AST:ALT ratio ≥ 2:1 with AST < 400–500 U/L is the classic LFT pattern of alcoholic hepatitis — due to B6 deficiency reducing ALT and mitochondrial AST release.
-
GGT is disproportionately elevated (inducible enzyme) and MCV is raised (direct membrane toxicity) — both are clues to alcohol as the aetiology.
-
The 4 conditions where AST > ALT: Alcoholic hepatitis, HCC, congestive heart failure, ischaemic hepatitis.
-
Portal hypertension can develop in alcoholic hepatitis EVEN WITHOUT established cirrhosis — due to sinusoidal compression by swollen hepatocytes and perisinusoidal fibrosis.
-
Always exclude concomitant liver disease (HBV, HCV, autoimmune, metabolic) — especially in HK where HBV + alcohol + MASLD overlap is common.
-
Scoring: Maddrey DF ≥ 32 or MELD ≥ 21 = severe alcoholic hepatitis. Child-Pugh and MELD score cirrhosis severity. Lille score at day 7 assesses steroid response.
-
Extra-hepatic clues to chronic alcoholism: Parotid enlargement, Dupuytren's contracture, peripheral neuropathy, proximal myopathy, macrocytosis, cardiomyopathy, chronic pancreatitis, cerebellar degeneration.
-
Women are more susceptible to ALD at lower doses due to lower gastric ADH, higher body fat percentage, and estrogen-mediated gut permeability.
Active Recall - Alcoholic Liver Disease (Definition to Clinical Features)
[1] Senior notes: Ryan Ho GI, p.306 (ALD natural history and classification) [2] Senior notes: Ryan Ho GI, p.306 (AFLD and Alcoholic Cirrhosis section) [3] WHO Global Status Report on Alcohol and Health (2024) [4] Senior notes: Block A - Abdominal distension: ascites and cirrhosis, p.2 (HK cirrhosis aetiology) [5] Senior notes: Block A - Gastrointestinal Data Interpretation, p.5 (excluding other causes in alcoholic liver disease) [6] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai), p.442 (causes of liver cirrhosis in HK) [7] Lecture slides: GC 240. MASLD and Alcoholic Liver Disease.pdf, p.16 (Alcoholic Hepatitis) [8] Lecture slides: Gastroenterology Hepatology Introduction to GI/Hepatology investigations from the abnormal.pdf, p.8 (AST:ALT pattern) [9] Senior notes: Block A - Introduction to GI/Hepatology investigations (LFT, Endoscopy), p.5 (AST > ALT exceptions) [10] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p.777–779 (ALD clinical manifestation) [11] Senior notes: Block A - Jaundice after raw oysters: acute hepatitis, p.2 (RUQ pain in hepatitis) [12] Senior notes: Block A - Introduction to GI/Hepatology investigations (LFT, Endoscopy), p.17 (alcoholic hepatitis hepatomegaly) [13] Senior notes: Ryan Ho Cardiology, p.169 (DCMP – alcoholic as toxic cause) [14] Senior notes: Block A - Upper abdominal pain: peptic ulcer; pancreatitis and gallstone, p.34 (chronic pancreatitis aetiology) [15] Lecture slides: GC 240. MASLD and Alcoholic Liver Disease.pdf, p.7 (Assessment: Liver Steatosis) [16] Lecture slides: CFB (MED07) Examination of the Abdomen.pdf [17] Senior notes: Block A - Gastroenterology Interactive Tutorial, p.2 (fatty liver classification) [18] Senior notes: Block A - WCS32 Chest pain on exertion: ischaemic heart disease; angina pectoris, p.11 (alcohol and CVS) [19] Lecture slides: GC 161. Alcohol and the Brain From Psychiatric to Neuropsychiatric Perspectives.pdf [20] Senior notes: Block A - I am a hepatitis B carrier, p.28 (causes of hepatitis flare-up)
Differential Diagnosis of Alcoholic Liver Disease
Before diving into lists, understand what you are actually differentiating. A patient with suspected ALD can present in several ways, and the differential diagnosis differs depending on the clinical scenario:
- Elevated liver enzymes (incidental finding) — "Why are the LFTs abnormal?"
- Hepatomegaly — "What is causing the large liver?"
- Acute hepatitis picture (jaundice + elevated transaminases) — "Is this alcoholic hepatitis, or something else?"
- Cirrhosis / decompensated chronic liver disease — "What is the aetiology of this cirrhosis?"
- Hepatic steatosis on imaging — "Alcohol, metabolic, or something else?"
The key teaching point: there is no laboratory test that can reliably differentiate alcoholic liver disease from other causes of liver diseases [21]. Determining the final diagnosis requires: history (drug history), clinical presentation, other investigations — liver biopsy may be required [8]. This means that ALD is partly a diagnosis of compatible history + exclusion of mimics.
Golden Rule
Anyone presenting with chronic liver disease and a history of alcoholism must exclude other causes [5]. Don't get fooled with alcoholic hepatitis — find out other things if possible. [5] A patient may drink heavily AND have HBV, HCV, autoimmune hepatitis, or MASLD simultaneously. The DI teaching clinic case demonstrated a patient thought to have alcoholic liver disease who actually had a positive HCV [5].
Approach: Differential Diagnosis by Presentation Scenario
When a patient has raised ALT/AST, you must first determine the pattern:
In usual circumstances, ALT level > AST level in diseases primarily affecting the liver, except: [8][9]
| Condition | AST:ALT Pattern | Distinguishing Clue |
|---|---|---|
| Alcoholic hepatitis | AST > ALT, ratio > 2:1; AST seldom > 500 U/L | ↑GGT, ↑MCV; history of heavy drinking |
| Hepatocellular carcinoma | AST > ALT | Viral markers, AFP, imaging |
| Congestive heart failure | AST > ALT | Clinical context; US liver — enlarged liver, engorged hepatic vein |
| Ischaemic hepatitis | AST > ALT | Profound shock; disproportionate increase in LDH |
So when you see AST > ALT, your differential immediately narrows to these four. The absolute level, clinical context, and ancillary tests help you distinguish further.
Alcoholic hepatitis: AST almost never greater than 500 U/L. Isolated rise in GGT with relatively normal ALP. Increase in MCV. [8][9] If transaminases are > 500 or > 1000, think viral hepatitis, ischaemic hepatitis, drug/toxin (paracetamol), or autoimmune hepatitis flare — NOT alcoholic hepatitis.
Differential diagnosis of hepatomegaly [22][23][24]:
| Category | Causes | Key Features |
|---|---|---|
| Steatosis | Alcoholic fatty liver disease; Non-alcoholic steatohepatitis (MASLD) | Smooth, firm liver; hyperechoic on USS |
| Hepatitis | Viral hepatitis (acute or chronic); Alcoholic hepatitis; Autoimmune hepatitis; Drug-induced liver injury (DILI) | Tender (if acute); smooth |
| Neoplasm — Benign | Haemangioma; Adenoma; Focal nodular hyperplasia | Usually focal; incidental |
| Neoplasm — Malignant | HCC; Cholangiocarcinoma; Metastases; Leukaemia; Lymphoma; Myeloma | Hard, nodular, ± bruit |
| Venous outflow obstruction | Right heart failure; Constrictive pericarditis; Budd-Chiari syndrome (hepatic vein thrombosis); IVC obstruction; Sinusoidal obstruction syndrome | Tender, ± pulsatile (TR) |
| Cholestatic | PBC; PSC; Biliary atresia | Cholestatic LFT pattern (↑ALP, ↑GGT) |
| Storage / Metabolic | Haemochromatosis; Wilson's disease; Glycogen storage disease; Gaucher disease; α1-antitrypsin deficiency; Amyloidosis | Specific metabolic workup |
| Miscellaneous | Polycystic liver disease; Liver abscess; Riedel's lobe (anatomical variant) | Imaging characteristic |
On abdominal examination, describe the hepatomegaly: [25]
- Irregular/hard → cancer (not only HCC!)
- Nodular → polycystic kidney and liver disease
- Smooth → fatty liver, alcoholic cirrhosis, primary biliary cholangitis (NOT chronic viral hepatitis unless superimposed pathology)
Alcoholic hepatitis is a known cause of hepatomegaly → usually a mild, soft hepatomegaly. Also try to look for enlarged parotid gland. [12] Alcoholic cirrhosis also causes hepatomegaly — hepatomegaly is common even with presence of cirrhosis [2] — this is unusual because most other forms of cirrhosis produce a shrunken liver.
When a patient presents with acute jaundice, you must differentiate alcoholic hepatitis from other causes of acute hepatitis:
| Differential | How It Differs from Alcoholic Hepatitis |
|---|---|
| Acute viral hepatitis (HAV, HBV, HCV, HEV) | ALT > AST (ALT typically predominates); transaminases often > 1000 U/L [11]; check viral serology |
| Drug-induced liver injury (DILI) | Temporal relationship with drug; paracetamol causes AST > 1000 with rapid rise/fall; drug history is key |
| Autoimmune hepatitis (AIH) | ANA, ASMA (anti-smooth muscle / anti-F-actin), anti-LKM-1 positive; ↑IgG [26][27]; female predominance; fluctuating course; may present with fulminant hepatic failure |
| Ischaemic hepatitis ("shock liver") | History of profound shock/haemodynamic instability; AST > ALT; disproportionate ↑LDH; rapid rise and fall of transaminases (peaks then improves in days once perfusion restored) [8][9][12] |
| Cholangiohepatitis (ascending cholangitis) | Charcot's triad (fever, jaundice, RUQ pain); ↑ALP and GGT; imaging shows biliary dilatation; rapid improvement in hours after biliary drainage |
| Wilson's disease (acute presentation) | Young patient; Coombs-negative haemolytic anaemia; low ceruloplasmin; KF rings; fulminant hepatic failure in a young patient with no other explanation + low Hb [28] |
| Acute HBV reactivation | HBsAg positive; may occur with immunosuppressant withdrawal (especially anti-CD20); IgM anti-HBc rises [20] |
| Hepatitis E | Travel history; seafood ingestion; anti-HEV IgM; increasingly recognised in HK [5] |
| HCC (with hepatic decompensation) | AST > ALT; AFP elevated; imaging shows mass [9][22] |
The lecture slides list four conditions where urgent imaging may NOT be necessary to make a diagnosis based on LFT pattern + clinical context: [8]
- Cholangiohepatitis
- Acute hepatitis E
- Ischaemic hepatitis
- Alcoholic hepatitis
For alcoholic hepatitis, must exclude: biliary obstruction (imaging) and other types of hepatitis [7].
When a patient presents with established cirrhosis, you need to identify the cause — and crucially, more than one cause may coexist (concept of concomitant liver disease [4]).
| Category | Causes | HK Prevalence |
|---|---|---|
| Infection | Chronic HBV (most common in HK, ~64–75%); Chronic HCV (~5–10%) | Dominant in HK |
| Metabolic/Toxic | ALD (~4%); MASLD/NASH; Wilson's disease; Haemochromatosis; α1-antitrypsin deficiency | ALD rising in HK |
| Autoimmune | Autoimmune hepatitis | Less common in HK |
| Biliary | PBC; PSC; Secondary biliary cirrhosis (stones/stricture/neoplasm/biliary atresia) | |
| Vascular | Budd-Chiari syndrome; Cardiac cirrhosis (RHF, MS/TR, constrictive pericarditis) | |
| Drug-induced | Methotrexate; Amiodarone | |
| Cryptogenic | Idiopathic — most likely HBV carriers with loss of HBsAg or burnt-out MASLD [6] |
Isolated increase in GGT → inducible enzyme → think alcohol [5]. An isolated GGT elevation with normal ALP in a patient with cirrhosis is a strong clue to alcohol as the aetiology (or at least a contributory factor).
When USS or CT shows steatosis:
Fatty liver classification: [17]
- Alcoholic fatty liver
- NASH / MAFLD (MASLD)
| Feature | ALD | MASLD |
|---|---|---|
| History | > 20–40 g/day alcohol | Metabolic syndrome (obesity, T2DM, dyslipidaemia) |
| AST:ALT | > 2:1 (reversed de Ritis) | < 1 (ALT > AST) |
| GGT | Disproportionately elevated | Mildly elevated |
| MCV | Elevated | Normal |
| Immunoglobulins | ↑IgA [26] | Normal or ↑IgG if NASH |
| Response | Resolves with abstinence | Requires weight loss / metabolic control |
| ANI score | > 0 favours ALD | < 0 favours NAFLD [2] |
ALD to NAFLD Index (ANI) = −58.5 + 0.637 × MCV + 3.91 × AST/ALT − 0.406 × BMI + 6.35 if male [2]. A score > 0 favours ALD; < 0 favours NAFLD. This is useful when the history is unreliable.
Other causes of hepatic steatosis to exclude:
- Drug-related: corticosteroids, tamoxifen, valproate, methotrexate [15]
- HCV-related steatosis [2]
- Endocrine: hypothyroidism, PCOS, panhypopituitarism [15]
- Others: bypass surgery, genetic (e.g., PNPLA3 polymorphism) [15]
Differential Diagnosis of Specific Complications in ALD
When a patient with known ALD decompensates or develops a new problem, each complication itself has a differential:
Key concept: confusion in cirrhosis does NOT mean hepatic encephalopathy. HE is a less common cause of confusion in cirrhosis. Confusion is still most commonly caused by head injury and drug-related causes [29].
Other differentials for confusion in cirrhosis:
- Head injury (alcoholics are prone to falls)
- Drug effects (benzodiazepines, opioids, sedatives)
- Alcohol withdrawal / delirium tremens
- Wernicke's encephalopathy (thiamine deficiency)
- Infection (SBP, pneumonia, UTI → septic encephalopathy)
- Metabolic disturbance (hypoglycaemia, hyponatraemia, hypokalaemia)
- Intracranial bleed (subdural haematoma — coagulopathy + falls)
- Hepatic encephalopathy (diagnosis by exclusion; no single diagnostic test; arterial ammonia is not diagnostic — not always raised, may not correlate with severity) [29]
For any patient with cirrhosis and confusion, must order CT brain and electrolyte panel, maybe even urine toxicology to exclude other causes [29].
Hepatorenal syndrome sounds like the obvious answer, but it is actually NOT the most common cause of AKI in liver disease [30]. Must consider:
- Pre-renal: Dehydration, GI bleeding, over-diuresis, sepsis
- Intrinsic renal: ATN, drug nephrotoxicity (NSAIDs, aminoglycosides, contrast), glomerulonephritis (IgA nephropathy in alcoholics; HCV-associated cryoglobulinaemic GN)
- Post-renal: Obstruction (rare in this context)
- Hepatorenal syndrome (HRS): Diagnosis of exclusion; requires absence of structural kidney disease, no improvement with volume expansion
Immunoglobulin pattern in different liver diseases: [26]
- ↑IgG = Autoimmune hepatitis
- ↑IgM = Primary biliary cholangitis (PBC)
- ↑IgA = Alcoholic hepatitis
This is a quick discriminator when the aetiology of chronic liver disease is unclear. Elevated IgA in ALD occurs due to chronic antigenic stimulation via the gut-liver axis (increased intestinal permeability → bacterial products stimulate mucosal IgA-producing B cells → spillover into systemic circulation).
Autoimmune hepatitis (AIH): [27]
- Chronic hepatitis of unknown aetiology
- Occurs in all age groups and both sexes across all ethnic groups — female predominance
- Variable clinical manifestation: fluctuating course; asymptomatic or insidious; acute severe flare; fulminant hepatic failure
- Autoantibodies:
- Anti-smooth muscle / anti-F-actin → Type 1
- Anti-liver kidney microsomal-1 → Type 2
- Anti-liver soluble antigen → Type 3
Why does AIH matter in the ALD differential? Because AIH can present with acute hepatitis mimicking alcoholic hepatitis (both cause jaundice + raised transaminases + hepatomegaly). The LFT pattern and autoantibody panel help differentiate. AIH may also coexist with ALD.
| Feature | ALD | MASLD | Viral Hepatitis | Autoimmune Hepatitis | Ischaemic Hepatitis |
|---|---|---|---|---|---|
| History | Heavy alcohol | Metabolic syndrome | Risk factors for HBV/HCV | Female, autoimmune Hx | Shock / haemodynamic instability |
| AST:ALT | > 2:1 | < 1 | ≈1, ALT predominant | Variable, often ALT > AST | > 1 |
| Transaminase level | < 500 | Mild (< 200) | Can be > 1000 | Variable (can be very high) | Can be > 1000 with rapid fall |
| GGT | Markedly ↑ | Mild ↑ | Variable | Variable | Variable |
| MCV | ↑ | Normal | Normal | Normal | Normal |
| Immunoglobulins | ↑IgA | Normal | Normal | ↑IgG | Normal |
| Specific markers | History, ANI | Metabolic workup | HBsAg, anti-HCV | ANA, ASMA, anti-LKM | LDH disproportionately ↑ |
| Liver biopsy | Mallory-Denk bodies, neutrophilic infiltrate, perivenular fibrosis | Ballooning, lobular inflammation | Interface hepatitis, lymphocytic | Interface hepatitis, plasma cells, rosettes | Zone 3 necrosis, congestion |
Exam Pitfall: Alcohol + Another Cause
The most common exam and clinical mistake is to stop at "alcoholic liver disease" when the patient clearly drinks. Always systematically exclude concomitant aetiologies — especially HBV (dominant in HK), HCV, MASLD, and autoimmune hepatitis. The teaching clinic repeatedly emphasises this: "Don't get fooled with alcoholic hepatitis — find out other things if possible." [5]
High Yield Summary
-
No single lab test reliably differentiates ALD from other liver diseases — diagnosis requires compatible history + exclusion of other causes.
-
AST:ALT > 2:1 with AST < 500, ↑GGT, ↑MCV = classic ALD pattern; but the 4 conditions with AST > ALT are: alcoholic hepatitis, HCC, CHF, ischaemic hepatitis.
-
Always exclude concomitant liver disease in HK: HBV, HCV, MASLD — dual/triple pathology is common.
-
Immunoglobulin pattern: ↑IgA = ALD; ↑IgG = AIH; ↑IgM = PBC.
-
Confusion in cirrhosis ≠ hepatic encephalopathy — head injury, drugs, withdrawal, infection, metabolic disturbance are commoner; HE is a diagnosis of exclusion.
-
Hepatomegaly in ALD: smooth, soft (fatty liver or alcoholic hepatitis) or smooth with nodules (cirrhosis) — contrast with hard, nodular (malignancy).
-
ANI score can help distinguish ALD from MASLD when history is unreliable (> 0 favours ALD, < 0 favours MASLD).
-
Liver biopsy may be required when diagnosis is unclear due to atypical features or possible concomitant disease — "only useful here" [8] for definitively distinguishing overlapping aetiologies.
Active Recall - Differential Diagnosis of Alcoholic Liver Disease
References
[2] Senior notes: Ryan Ho GI, p.306–307 (ALD classification, AFLD, ANI score, diagnostic evaluation) [4] Senior notes: Block A - Abdominal distension: ascites and cirrhosis, p.2 (HK cirrhosis aetiology, concomitant liver disease) [5] Senior notes: Block A - Gastrointestinal Data Interpretation, p.5 (excluding other causes, HCV case, isolated GGT, Child-Pugh and MELD) [6] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai), p.442 (causes of liver cirrhosis) [7] Lecture slides: GC 240. MASLD and Alcoholic Liver Disease.pdf, p.16 (Alcoholic Hepatitis features and exclusions) [8] Lecture slides: Gastroenterology Hepatology Introduction to GI/Hepatology investigations from the abnormal.pdf, p.8, p.49 (AST:ALT pattern, workshop conclusions) [9] Senior notes: Block A - Introduction to GI/Hepatology investigations (LFT, Endoscopy), p.5, p.16–17 (4 exceptions AST > ALT, ischaemic hepatitis, alcoholic hepatitis hepatomegaly) [11] Senior notes: Block A - Jaundice after raw oysters: acute hepatitis, p.2 (biochemistry of hepatitis, RUQ pain) [12] Senior notes: Block A - Introduction to GI/Hepatology investigations (LFT, Endoscopy), p.17 (alcoholic hepatitis hepatomegaly, parotid gland) [15] Lecture slides: GC 240. MASLD and Alcoholic Liver Disease.pdf, p.7 (Assessment: Liver Steatosis) [17] Senior notes: Block A - Gastroenterology Interactive Tutorial, p.2 (fatty liver classification) [20] Senior notes: Block A - I am a hepatitis B carrier, p.28 (causes of hepatitis flare-up) [21] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p.781 (no single lab test differentiates ALD) [22] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p.825 (differential diagnosis of hepatomegaly) [23] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai), p.481 (differential diagnosis of hepatomegaly) [24] Lecture slides: WCS 064 - A large liver - by Prof R Poon, p.2 (hepatomegaly differential diagnosis) [25] Lecture slides: abdominal exam (MBBS IV) (student version), p.24 (describe hepatomegaly) [26] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p.732 (immunoglobulin pattern, autoantibodies) [27] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2, p.5 (autoimmune hepatitis) [28] Senior notes: Block A - Patients with non-viral chronic liver diseases, p.2 (Wilson's disease, Coombs-negative haemolytic anaemia) [29] Senior notes: Block A - A jaundiced and incoherent patient: liver failure, p.17 (confusion in cirrhosis, HE diagnosis by exclusion) [30] Senior notes: Block A - Abdominal distension: ascites and cirrhosis, p.20 (AKI in liver disease, HRS)
Diagnostic Criteria, Algorithm & Investigations for Alcoholic Liver Disease
There is no single pathognomonic blood test, imaging finding, or biomarker that definitively confirms alcoholic liver disease. Determining the final diagnosis requires: history (drug history), clinical presentation, other investigations — liver biopsy may be required [8]. There is no laboratory test that can reliably differentiate alcoholic liver disease from other causes of liver diseases [21].
The diagnosis rests on three pillars:
- Compatible history of significant alcohol consumption.
- Characteristic clinical and laboratory pattern (AST:ALT ≥ 2:1, ↑GGT, ↑MCV, ± hepatic decompensation).
- Exclusion of other causes of liver disease (viral, autoimmune, metabolic, drug-induced, biliary).
Think of it like a Venn diagram: the diagnosis sits at the intersection of "drinks enough alcohol" + "right pattern of liver injury" + "nothing else explains it better."
Diagnostic Criteria
There are no formal "diagnostic criteria" per se. Diagnosis is made when:
- History of significant alcohol intake (typically > 20 g/day women, > 40 g/day men).
- Imaging demonstrates hepatic steatosis (USS: hyperechoic liver; CT: low-attenuation liver).
- Other causes of steatosis are excluded or accounted for.
- Can be detectable by USG, despite liver biopsy showing macrovesicular fat droplets in centrilobular zones being the gold standard [31].
Alcoholic hepatitis is the entity where diagnostic criteria matter most, because it has specific prognostic scoring and treatment thresholds.
NIAAA (National Institute on Alcohol Abuse and Alcoholism) Diagnostic Criteria for Alcoholic Hepatitis (2024 ACG/AASLD consensus):
| Criterion | Detail |
|---|---|
| 1. Alcohol use | Prolonged heavy drinking (> 50–60 g/day) [7]; onset of jaundice within 60 days of last heavy drinking |
| 2. Jaundice | Serum total bilirubin > 51 μmol/L (> 3 mg/dL) |
| 3. AST:ALT pattern | AST:ALT ratio ≥ 1.5:1 (AST seldom > 400 U/L) [7][9] |
| 4. Exclusion of other causes | Exclude biliary obstruction (imaging) and other types of hepatitis [7] |
| 5. No confounders | No sepsis, shock (ischaemic hepatitis), cocaine use, or recent DILI to explain the picture |
GC Lecture Slide — Core Diagnostic Features of Alcoholic Hepatitis
Alcoholic Hepatitis [7]:
- Prolonged heavy drinking (> 50–60 g/day)
- May cut down recently due to symptoms
- AST:ALT ratio of ≥ 1.5:1 (AST seldom > 400 U/L)
- May have hepatic decompensation (↑INR, Bilirubin)
- +/- abdominal discomfort / jaundice / low-grade fever
- +/- haemolysis (Zieve's syndrome)
- Exclude: biliary obstruction (imaging); other types of hepatitis
- +/- concomitant cirrhotic complications
Classification of diagnostic certainty (NIAAA framework):
| Level | Criteria |
|---|---|
| Definite AH | Clinical criteria met + liver biopsy confirms (steatosis + hepatocyte ballooning + neutrophilic lobular inflammation ± Mallory-Denk bodies) |
| Probable AH | Clinical criteria met, no biopsy performed, no confounders |
| Possible AH | Clinical criteria met but confounders present (e.g., possible concurrent DILI, unclear drug history, atypical features) |
In clinical practice, most cases are diagnosed as "probable AH" without biopsy, because biopsy carries risks in coagulopathic patients and the clinical-laboratory picture is usually sufficient.
Diagnosis follows the same principles as cirrhosis of any aetiology:
- Clinical: Stigmata of chronic liver disease + signs of portal hypertension + history of heavy alcohol use.
- Laboratory: Features of hepatic decompensation (↑bilirubin, ↓albumin, ↑INR) + ALD pattern (↑GGT, ↑MCV, AST > ALT).
- Imaging: Nodular liver surface, features of portal hypertension.
- Non-invasive fibrosis assessment: Elastography (FibroScan) — liver stiffness > 12 kPa suggestive of cirrhosis [17].
- Histological definition: late stage of liver fibrosis (F4) with diffuse distortion of liver architecture and formation of regenerative nodules surrounded by fibrous bands [4].
Once you diagnose alcoholic hepatitis, the next critical question is: how severe is it? This determines whether the patient needs specific pharmacotherapy (corticosteroids).
| Score | Formula / Parameters | Threshold | Purpose |
|---|---|---|---|
| Maddrey Discriminant Function (mDF) | 4.6 × (PT patient − PT control in seconds) + total bilirubin (mg/dL) | ≥ 32 = severe AH → indication for corticosteroids [31][32] | Identifies patients with high short-term mortality who benefit from prednisolone |
| MELD score | 3.78 × ln(bilirubin mg/dL) + 11.2 × ln(INR) + 9.57 × ln(creatinine mg/dL) + 6.43 | ≥ 21 = high 90-day mortality | Also used for transplant prioritisation [5] |
| Lille score | Calculated at day 7 of steroid therapy using: age, albumin, bilirubin day 0, bilirubin day 7, creatinine, PT | > 0.45 = steroid non-responder → consider stopping steroids | Assesses early response to steroids |
| Glasgow Alcoholic Hepatitis Score (GAHS) | Age, WCC, urea, INR, bilirubin | ≥ 9 = poor prognosis | Alternative to mDF |
| ABIC score | Age, bilirubin, INR, creatinine | Stratifies into low, intermediate, high risk | Less commonly used |
Child-Pugh score (5 parameters: albumin, bilirubin, INR/PT, ascites, encephalopathy — A/B/C) and MELD score (3 parameters: bilirubin, INR, creatinine) are used for overall cirrhosis severity staging. In HK, transplantation priority is based on MELD — not first come first served [5].
mDF: The Number to Remember
Maddrey DF ≥ 32 is the threshold for starting corticosteroids [31][32]. The formula is elegant in its simplicity — it combines coagulopathy (PT prolongation reflects severity of synthetic dysfunction) with cholestasis (bilirubin reflects degree of hepatocyte damage and bile flow impairment). A higher number means more severe hepatocyte injury.
Before you can diagnose ALD, you need to identify problematic alcohol use. Validated screening tools:
CAGE questionnaire [32]:
- Cut down: Have you ever felt you should cut down on your drinking?
- Annoyed: Have people annoyed you by criticising your drinking?
- Guilty: Have you ever felt guilty about your drinking?
- Eye-opener: Have you ever had a drink first thing in the morning (eye-opener) to steady your nerves or get rid of a hangover?
≥ 2 positive answers = positive screen for alcohol use disorder [32].
Other tools: AUDIT (Alcohol Use Disorders Identification Test — 10-item WHO questionnaire), AUDIT-C (3-item abbreviated version), SADQ (Severity of Alcohol Dependence Questionnaire — > 30 = indication for in-patient detoxification [33]).
Safety drinking limits: 1 unit = 8 g; 2–3 units/day (male), 1–2 units/day (female) [32].
The following algorithm represents the systematic approach to diagnosing ALD and its stages:
Investigation Modalities: What to Order and How to Interpret
1. Blood Investigations
LFTs assess three distinct aspects of hepatic function: [34]
- Cellular integrity: ALT and AST
- Synthetic capacity: albumin and prothrombin time (INR)
- Excretory function: bilirubin, ALP, and GGT
| Parameter | Expected in ALD | Interpretation & Mechanism |
|---|---|---|
| AST | ↑, but < 300–500 U/L | Released from damaged hepatocytes and mitochondria; higher in ALD due to mAST release from alcohol-damaged mitochondria |
| ALT | ↑, but less than AST | Reduced due to pyridoxal-5-phosphate (B6) deficiency in alcoholics |
| AST:ALT ratio | ≥ 1.5–2:1 [7][8][9] | "The AST:ALT ratio provides crucial diagnostic clues beyond absolute enzyme levels. A ratio exceeding 2:1 strongly suggests alcoholic hepatitis" [34] |
| GGT | Markedly elevated; ↑↑↑ GGT with ↑ ALP [31] | GGT is an inducible enzyme; isolated rise in GGT with relatively normal ALP → think alcohol [5][9]. Alcohol directly induces microsomal GGT synthesis in hepatocytes. Also released from damaged bile duct epithelium. |
| ALP | Mildly to moderately elevated | Cholestatic component from swollen hepatocytes compressing canaliculi; ALP rise is modest compared to GGT |
| Bilirubin | Elevated (conjugated predominant) | Impaired hepatocyte excretion + intrahepatic cholestasis; key component of mDF and MELD |
| Albumin | Low in cirrhosis/severe AH | ↓ Hepatic synthetic function; t₁/₂ ≈ 21 days, so reflects chronic rather than acute changes |
Elevation of AST and ALT is usually < 10× upper limit of normal. AST level ≥ 2× ALT level [31].
The GGT Clue
An isolated increase in GGT → inducible enzyme → think alcohol [5]. GGT (gamma-glutamyl transferase) sits on the canalicular surface of hepatocytes and in bile duct epithelium. Alcohol upregulates its expression at the gene level (enzyme induction), so GGT rises out of proportion to other cholestatic markers. This is why a disproportionately elevated GGT with only mild ALP elevation is a red flag for alcohol.
| Parameter | Expected | Why |
|---|---|---|
| PT / INR | Prolonged / ↑ [31] | Factor VII (shortest t₁/₂ = 6 hours among clotting factors) is synthesised in the liver → earliest clotting factor to fall in hepatocyte dysfunction. INR is the best marker for monitoring progress and prognosis [11]. |
| APTT | May be prolonged | Factors IX, X, XI also hepatically synthesised; prolonged in advanced liver disease |
Distinguishing vitamin K deficiency from true synthetic failure: [35]
- Jaundice + ↑PT → could be cholestasis (impaired bile → impaired fat-soluble vitamin K absorption) OR hepatocellular failure.
- Give IV vitamin K (10 mg × 3 days): if PT corrects → cholestasis (vitamin K deficiency); if PT does NOT correct → hepatocellular failure (no functional hepatocytes to use vitamin K).
- In warfarin use: ↑PT, ± ↑APTT. In liver disease: ↑PT [35].
| Parameter | Finding | Mechanism |
|---|---|---|
| MCV | ↑ (macrocytosis) [9][31] | Toxic alcohol permeates RBC membrane and alters lipid structures [9] + folate/B12 deficiency. MCV can be elevated even without anaemia. |
| Haemoglobin | Low (anaemia) | Multifactorial: GI bleeding, folate deficiency, direct marrow suppression, haemolysis (Zieve's syndrome) [7], hypersplenism |
| WCC | Elevated (neutrophilia) | Inflammatory response — TNF-α, IL-8 drive neutrophil recruitment to liver |
| Platelets | Low | Hypersplenism from portal hypertension [5]; direct marrow suppression by ethanol; ↓hepatic thrombopoietin production |
| Reticulocytes | May be elevated | If haemolysis or active bleeding |
Pancytopenia (hypersplenism) can occur in advanced ALD with portal hypertension [31].
| Test | Purpose | Expected Finding in ALD |
|---|---|---|
| Plasma glucose | Hypoglycaemia screen | Hypoglycaemia [32] — ethanol inhibits gluconeogenesis (NADH/NAD⁺ imbalance); particularly in fasting alcoholics |
| Lipid profile | Dyslipidaemia screen | Hypertriglyceridaemia (impaired VLDL secretion, ↑hepatic lipogenesis); hypercholesterolaemia in Zieve's syndrome [31] |
| Serum IgA | Immunoglobulin pattern | ↑IgA in ALD (gut-liver axis chronic antigenic stimulation) [26] |
| Urea and creatinine | Renal function | Elevated urea:creatinine ratio if GI bleeding (digestion of blood protein → urea) [36]; creatinine for MELD and HRS assessment |
| Electrolytes | Metabolic derangement | Hypokalaemia, hypomagnesaemia, hypophosphataemia (common in alcoholics — refeeding risk) |
| Blood alcohol level | Confirms recent intake | May be negative if the patient stopped drinking days before admission |
| Arterial ammonia | Hepatic encephalopathy assessment | Not always raised, may not correlate with severity [29]; supportive but not diagnostic of HE |
Must order in every case [5]:
| Marker | What It Tests |
|---|---|
| HBsAg | Active HBV infection |
| Anti-HBs, Anti-HBc | Prior exposure/immunity |
| IgM anti-HBc | Acute HBV or acute flare of chronic HBV |
| HBeAg, Anti-HBe | HBV replication status |
| HBV DNA | Viral load — the most important marker to assess disease progression in chronic HBV [37] |
| Anti-HCV | HCV exposure |
| HCV RNA | Active HCV infection (if anti-HCV positive) — HCV can be eradicated; 20% will clear spontaneously [5] |
| IgM anti-HAV | Acute HAV |
| Anti-HEV IgM | Acute HEV (increasingly important in HK) |
Autoimmune hepatitis is very difficult to diagnose, sometimes becomes a diagnosis of exclusion. Autoantibodies are not specific, require diagnostic criteria [38].
| Test | Purpose | Interpretation |
|---|---|---|
| ANA, ASMA / anti-F-actin | Type 1 AIH | ASMA titres > 1:320 generally reflects anti-actin antibodies [26] |
| Anti-LKM-1 | Type 2 AIH | Antibodies against CYP2D6 |
| Total IgG / gamma globulin | AIH screen | ↑IgG = AIH [26] |
| AMA (anti-mitochondrial Ab) | PBC | M2 isoform highly specific for PBC [28] |
| Serum ferritin, transferrin saturation | Haemochromatosis | Transferrin sat > 45% and ferritin elevated → consider HFE gene testing |
| Serum ceruloplasmin | Wilson's disease | Low in Wilson's (< 0.2 g/L); genetic test does not have to be positive to diagnose — very heterogeneous [28] |
| Alpha-1 antitrypsin level | α1-AT deficiency | Low level + PiZZ phenotype |
| AFP | HCC screening | Normal < 6–12 ng/mL; raised in 80% of HCC [22] |
2. Imaging Investigations
Why USS is first-line: non-invasive, no radiation, widely available, inexpensive, and provides information on multiple aspects simultaneously.
| Finding | What It Tells You |
|---|---|
| Hyperechoic liver ("bright liver") | Detection of hepatic steatosis [21] — fat is echogenic; increased echogenicity compared to renal cortex indicates steatosis |
| Deep attenuation | Fat absorbs ultrasound waves → posterior structures are poorly visualised |
| Coarse echo pattern | Detection of fibrosis [21] — indicates chronicity |
| Nodular surface, irregular outline | Detection of cirrhosis [21] — regenerative nodules distort the smooth liver surface |
| Portal vein flow reversal | Evaluation of portal hypertension [21] — hepatofugal flow indicates significant portal HTN |
| Splenomegaly | Congestive splenomegaly from portal hypertension |
| Ascites | Free fluid in peritoneal cavity |
| Liver mass | HCC screening (heterogeneous mass in cirrhotic liver) |
| Enlarged liver with engorged hepatic vein | Congestive heart failure [9] — a key differentiator from primary liver disease |
| Biliary dilatation | Excludes extrahepatic obstruction — must exclude biliary obstruction [7] |
Emerging modality for evaluating fatty liver and fibrosis [2]:
| Measurement | What It Assesses | Interpretation |
|---|---|---|
| Liver stiffness (kPa) | Degree of hepatic fibrosis | < 7 kPa = unlikely significant fibrosis; 7–12 kPa = possible significant fibrosis; > 12 kPa = suggestive of cirrhosis [17] |
| CAP score (dB/m) | Controlled Attenuation Parameter — quantifies steatosis | 248–280 dB/m = mild-moderate steatosis; > 280 dB/m = severe steatosis [17] |
FibroScan is increasingly replacing liver biopsy as the initial assessment tool for fibrosis staging. It is non-invasive, reproducible, and can be performed at the bedside. However, results can be falsely elevated by acute inflammation (alcoholic hepatitis), obesity, and recent food intake.
Platelet Count as a Non-Invasive Fibrosis Marker
Platelet count is important in assessing fibrosis [15]. A low platelet count in the context of liver disease suggests portal hypertension (hypersplenism) and advanced fibrosis. This is incorporated into the FIB-4 score:
FIB-4 = [Age × AST] / [Platelet count (10⁹/L) × √ALT]
< 1.3 = low risk of advanced fibrosis; > 2.67 = high risk. Simple, free, and can be calculated from routine bloods.
| Finding | Interpretation |
|---|---|
| Low-attenuation liver on non-contrast CT | Hepatic steatosis (liver density < spleen density) |
| Nodular parenchyma, attenuation of vasculature | Cirrhosis |
| Atrophy of right lobe, hypertrophy of caudate lobe | Advanced cirrhosis (caudate lobe has separate venous drainage → preserved) |
| Venous collaterals, splenomegaly, ascites | Portal hypertension |
| Arterially enhancing mass with washout | HCC (classic triphasic pattern) |
- Gradient-echo sequences are sensitive for detecting steatosis.
- MR elastography (MRE) is the most accurate non-invasive method for staging fibrosis but is expensive and not widely available.
- MRI with contrast (e.g., Eovist/Primovist) for HCC characterisation.
3. Liver Biopsy — Gold Standard but Not Always Needed
Liver biopsy may be necessary in patients with suspected alcoholic liver disease when diagnosis is unclear due to atypical features or possible concomitant disease [21].
- Diagnostic uncertainty (atypical clinical or laboratory features).
- Suspected concomitant liver disease (e.g., ALD + AIH, ALD + HCV).
- To establish severity of fibrosis when non-invasive methods are inconclusive.
- It is the ONLY method to distinguish between simple steatosis and steatohepatitis [2] — only the latter is associated with increased liver-related morbidity.
| Stage | Key Histological Features |
|---|---|
| Steatosis | Macrovesicular fat droplets in centrilobular (Zone 3) hepatocytes; nucleus displaced to periphery |
| Steatohepatitis | Hepatocyte ballooning degeneration (swollen, pale hepatocytes with wispy cytoplasm) + Mallory-Denk bodies (eosinophilic cytoplasmic inclusions composed of damaged intermediate filaments/cytokeratin) + neutrophilic lobular infiltrate ("satellitosis" — neutrophils surrounding ballooned hepatocytes) + pericellular/perivenular fibrosis ("chicken-wire" pattern in Zone 3) |
| Fibrosis → Cirrhosis | Progressive perisinusoidal and perivenular fibrosis → bridging fibrosis → micronodular cirrhosis (< 3 mm nodules, "Laennec cirrhosis") with regenerative nodules surrounded by fibrous septa |
Additional features that may be seen:
- Canalicular cholestasis (bile plugs in dilated canaliculi).
- Marked ductular reaction (proliferating bile ductules at fibrotic septa).
- Acute inflammation in portal regions.
- Periportal fibrosis.
- Giant mitochondria (megamitochondria) — reflecting chronic ethanol-induced mitochondrial injury.
These features (canalicular cholestasis, marked ductular reaction, acute inflammation in portal regions, periportal fibrosis) are more common in ALD than in MASLD and can help distinguish the two histologically [2].
- Bleeding tendency (INR > 1.2 despite vitamin K)
- Thrombocytopenia (platelets < 50 × 10⁹/L)
- High-grade biliary obstruction (risk of bile peritonitis)
- Massive ascites (relative)
- If percutaneous biopsy is contraindicated, transjugular liver biopsy can be performed (also allows measurement of hepatic venous pressure gradient — HVPG).
Not for diagnosing ALD per se, but essential in ALD patients with suspected or confirmed cirrhosis:
- Screen for oesophageal and gastric varices — all patients with newly diagnosed alcoholic cirrhosis should undergo OGD for variceal screening.
- Identify sources of upper GI bleeding (variceal vs. non-variceal).
- Low platelet count → hypersplenism → think about variceal bleeding [5].
| Investigation | When to Order | Rationale |
|---|---|---|
| Diagnostic paracentesis | Any cirrhotic patient with new or worsening ascites | SBP requires high clinical suspicion; may not have a lot of abdominal signs since no perforation; culture not useful (usually negative) — defined by checking the neutrophils (PMN ≥ 250/mm³) [5] |
| Urine toxicology | Confusion in cirrhotic patient | To exclude drug-related causes of confusion [29] |
| CT brain | Confusion in cirrhotic patient | Must order to exclude head injury, subdural haematoma [29] (alcoholics prone to falls + coagulopathic) |
| ECG / Echocardiography | If clinical suspicion of cardiomyopathy | Alcoholic dilated cardiomyopathy; also to exclude cardiac cirrhosis (RHF → congestive hepatopathy) |
| Hepatic venous pressure gradient (HVPG) | Research / specialist centres | Direct measure of portal hypertension; > 10 mmHg = clinically significant; > 12 mmHg = risk of variceal bleeding. Measured via transjugular approach. |
| Step | What You Do | Why |
|---|---|---|
| 1. History | Detailed alcohol intake (quantity, duration, pattern); CAGE/AUDIT screen | Establish exposure; may cut down recently due to symptoms [7] |
| 2. Baseline bloods | LFT, CBC, clotting, RFT, glucose, lipids | Identify ALD pattern (AST > ALT, ↑GGT, ↑MCV, ↑INR, ↓albumin, ↓platelets) |
| 3. Exclude other causes | Viral serology (HBV, HCV, HAV, HEV), autoimmune panel (ANA, ASMA, anti-LKM, IgG), metabolic screen (ferritin, ceruloplasmin, α1-AT), drug history, AFP | Don't get fooled — must exclude concomitant causes [5] |
| 4. Imaging | USS liver (first-line); ± CT/MRI; ± FibroScan | Assess steatosis, fibrosis, cirrhosis, exclude biliary obstruction and HCC |
| 5. Severity scoring | mDF, MELD, Child-Pugh | Guide management (steroids if mDF ≥ 32) and transplant listing |
| 6. Biopsy | Only if diagnostic uncertainty or suspected concomitant disease | ONLY useful here [8] — gold standard but not always needed |
| 7. Complication screening | OGD for varices; diagnostic paracentesis for SBP; AFP + USS 6-monthly for HCC | Cirrhotic patients require ongoing surveillance |
High Yield Summary
-
ALD is a clinical diagnosis — compatible history + characteristic lab pattern + exclusion of other causes. No single test is pathognomonic.
-
The diagnostic lab triad of ALD: AST:ALT ≥ 2:1 (AST < 500), disproportionately ↑GGT, ↑MCV.
-
For alcoholic hepatitis, must exclude biliary obstruction (imaging) and other types of hepatitis — viral serology, autoimmune panel, metabolic screen, and drug history are mandatory.
-
Severity scoring: mDF ≥ 32 → severe AH → steroids. Lille score > 0.45 at day 7 → steroid non-responder → stop. MELD ≥ 21 → high mortality.
-
CAGE questionnaire (≥ 2 positive = positive screen) is the quick bedside screening tool for alcohol use disorder.
-
USS liver is first-line imaging — detects steatosis (hyperechoic), fibrosis (coarse echo), cirrhosis (nodular surface), and excludes biliary obstruction.
-
FibroScan: liver stiffness > 12 kPa suggests cirrhosis; CAP score > 280 dB/m suggests severe steatosis.
-
Liver biopsy is gold standard but reserved for diagnostic uncertainty — histological hallmarks are macrovesicular steatosis, ballooning, Mallory-Denk bodies, neutrophilic infiltrate, and perivenular fibrosis.
-
SBP is diagnosed by ascitic fluid PMN ≥ 250/mm³, not by culture (culture often negative).
-
Always check viral markers in a patient with ALD — concomitant HBV/HCV is common in HK and changes management.
Active Recall - Diagnostic Criteria, Algorithm & Investigations for ALD
References
[2] Senior notes: Ryan Ho GI, p.306–307, p.310 (AFLD diagnostic evaluation, ANI score, liver biopsy, FibroScan) [4] Senior notes: Block A - Abdominal distension: ascites and cirrhosis, p.2 (cirrhosis definition, HK aetiology) [5] Senior notes: Block A - Gastrointestinal Data Interpretation, p.5 (isolated GGT, exclude other causes, SBP diagnosis, Child-Pugh/MELD, HCV) [7] Lecture slides: GC 240. MASLD and Alcoholic Liver Disease.pdf, p.16 (Alcoholic Hepatitis diagnostic features) [8] Lecture slides: Gastroenterology Hepatology Introduction to GI/Hepatology investigations from the abnormal.pdf, p.49 (conclusions for workshop cases, liver biopsy) [9] Senior notes: Block A - Introduction to GI/Hepatology investigations (LFT, Endoscopy), p.5 (AST:ALT pattern, GGT, MCV) [11] Senior notes: Block A - Jaundice after raw oysters: acute hepatitis, p.2 (INR for prognosis monitoring) [15] Lecture slides: GC 240. MASLD and Alcoholic Liver Disease.pdf, p.7 (Assessment: Liver Steatosis, platelet count) [17] Senior notes: Block A - Gastroenterology Interactive Tutorial, p.2 (FibroScan thresholds, CAP score) [21] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p.781 (no single lab test, USS, CT, MRI findings) [22] Senior notes: Maksim Surgery Notes, p.124–125 (AFP, liver biopsy contraindications) [26] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p.732 (immunoglobulin pattern, autoantibodies) [28] Senior notes: Block A - Patients with non-viral chronic liver diseases, p.1–2 (AIH, PBC, Wilson's) [29] Senior notes: Block A - A jaundiced and incoherent patient: liver failure, p.17 (confusion in cirrhosis, HE diagnosis) [31] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p.784–786 (ALD lab findings, mDF, USS gold standard) [32] Senior notes: Maksim Medicine Notes, p.147 (CAGE, safety limits, mDF formula, investigations for alcoholism) [33] Senior notes: Ryan Ho Psychiatry, p.106 (SADQ, CIWA-Ar, alcohol withdrawal assessment) [34] Senior notes: Learning_Points_All_Lectures.txt (LFT three aspects, AST:ALT ratio diagnostic clues) [35] Senior notes: Block A - Abnormal bleeding after tooth extraction, p.10 (PT in liver disease vs vitamin K deficiency) [36] Senior notes: Block A - Coffee ground vomitus tarry stool upper GI bleeding, p.9 (urea:creatinine ratio in bleeding) [37] Senior notes: Block A - I am a hepatitis B carrier, p.34 (HBV DNA most important marker) [38] Senior notes: Block A - Gastrointestinal Data Interpretation, p.2 (autoimmune hepatitis diagnosis of exclusion)
Management of Alcoholic Liver Disease
The management of ALD follows a logical hierarchy that mirrors the disease spectrum. At every stage, the same foundational question must be asked: "Is the patient still drinking?" — because no pharmacological or surgical intervention will work if the patient continues to consume alcohol.
The management framework has five pillars:
- Alcohol abstinence — the cornerstone at every stage.
- Nutritional rehabilitation — chronically malnourished patients cannot heal.
- Pharmacotherapy — mainly for severe alcoholic hepatitis (corticosteroids).
- Management of cirrhotic complications — portal hypertension, ascites, variceal bleeding, HE, HCC surveillance.
- Liver transplantation — the final line for end-stage disease.
Pillar 1: Alcohol Abstinence
Alcohol abstinence is the cornerstone of treatment of alcoholic liver disease [39].
This is not merely a "lifestyle recommendation" — it is the single most effective therapeutic intervention across all stages of ALD and has more evidence behind it than any drug.
Alcohol abstinence is associated with improved outcome in terms of: [2]
- Histology (reversal of steatosis, reduction of inflammation)
- ↓ Progression to cirrhosis
- ↓ Portal pressure
- ↓ Rebleeding from varices
- ↑ Survival
Steatosis can be completely reversed, but fibrosis/cirrhosis cannot — however, abstinence is still associated with better outcome even in the latter [2].
To put it bluntly: even if the damage is done and cirrhosis is established, stopping alcohol still saves lives. The 5-year survival for abstinent cirrhotics is ~60% versus ~30% for those who continue drinking [2].
Managing Alcohol Cessation in Hospital
When you admit an alcoholic patient, they are at risk of alcohol withdrawal — a potentially life-threatening condition. Management must be proactive.
Alcohol withdrawal develops within hours to days after cessation of or reduction in heavy alcohol use [33].
| Stage | Timing | Features |
|---|---|---|
| Minor withdrawal | 6–24 hours | Tremor, anxiety, insomnia, tachycardia, diaphoresis, nausea |
| Alcoholic hallucinosis | 12–48 hours | Visual/auditory hallucinations with intact sensorium |
| Withdrawal seizures | 12–48 hours | Generalised tonic-clonic seizures |
| Delirium tremens (DT) | 48–96 hours | Confusion, agitation, autonomic instability, hallucinations, fever — mortality ~5–15% if untreated |
Management of alcohol withdrawal: [33]
| Intervention | Detail | Mechanism / Rationale |
|---|---|---|
| Benzodiazepines | Prefer long-acting BDZs: diazepam (Valium) or chlordiazepoxide (Librium) [33] | BDZs enhance GABA-A receptor activity, compensating for the loss of alcohol's GABAergic effect. Long-acting agents provide smoother withdrawal curve. |
| Symptom-triggered dosing | CIWA-Ar scale ≥ 8 triggers dosing [33] | More effective and uses less total BDZ than fixed-schedule dosing; requires intensive monitoring (Q1h assessments) |
| If severe liver disease present | Use oxazepam [33] | Oxazepam undergoes glucuronidation only (no CYP450 oxidation) → safe in hepatic impairment. Diazepam is CYP-dependent → accumulates in liver failure. |
| Barbiturates or propofol | For refractory delirium tremens [33] | When BDZs are insufficient to control agitation |
| Thiamine + glucose | To prevent Wernicke's encephalopathy [33] | Always give thiamine BEFORE glucose — glucose metabolism consumes thiamine, and giving glucose first to a thiamine-depleted patient can precipitate Wernicke's. |
Thiamine BEFORE Glucose — A Classic Exam Point
In an alcoholic patient, always administer IV thiamine before any glucose-containing fluids. Glucose is metabolised via the pyruvate dehydrogenase complex, which requires thiamine (vitamin B1) as a cofactor. If thiamine is already depleted (as in chronic alcoholism), giving glucose without thiamine first will push the remaining thiamine into carbohydrate metabolism, precipitating acute Wernicke's encephalopathy (confusion, ophthalmoplegia, ataxia).
Withdrawal prophylaxis: [33]
- Oral chlordiazepoxide (Librium)
- Indication: patients with ↑ risk of severe withdrawal (history of seizures/DT) after heavy alcohol consumption, who are admitted for other reasons with minimal current withdrawal symptoms
- SADQ > 30 (severe dependence)
- History of severe withdrawal symptoms (seizures, DT)
- Very high alcohol consumption (> 30 units/day)
- Concomitant benzodiazepine misuse (synergistic withdrawal)
- Significant medical or psychiatric comorbidity
| Agent | Mechanism | Notes |
|---|---|---|
| Naltrexone | Opioid receptor antagonist → blocks the "rewarding" effect of alcohol (endorphin release) | Oral or IM depot; avoid in acute hepatitis or liver failure (hepatotoxic at high doses); CI if on opioids |
| Acamprosate | NMDA receptor modulator → reduces glutamate-mediated craving and dysphoria | Renally excreted → safe in liver disease; avoid if CrCl < 30 |
| Disulfiram | Irreversible ALDH inhibitor → acetaldehyde accumulates → severe flushing, nausea, vomiting after alcohol intake ("disulfiram reaction") | Patient must be fully informed and motivated; dangerous if patient drinks; contraindicated in decompensated liver disease, CVD |
| Psychosocial interventions | Motivational interviewing, cognitive-behavioural therapy, Alcoholics Anonymous, family therapy | Essential adjunct; pharmacotherapy alone has limited long-term success |
No alcohol for life for chronic hepatitis / chronic liver disease [40]. Only modification needed in hepatitis management is ALCOHOL [40].
Pillar 2: Nutritional Support
Good nutrition is critical [39]. Alcohol has high calorie content (7 kcal/g — "empty calories" with no nutritional value), so alcoholic patients often have a paradoxically high calorie intake but severe protein-calorie malnutrition because they substitute food with alcohol.
Protein calorie malnutrition may ↑ risk of major complications eg. infection, HE, ascites [2].
- Reduced food intake: Alcohol suppresses appetite; social dysfunction; gastritis causing nausea.
- Malabsorption: Alcohol damages intestinal mucosa; chronic pancreatitis → exocrine insufficiency → fat malabsorption.
- Impaired hepatic metabolism: Damaged liver cannot process nutrients effectively.
- Increased metabolic demands: Inflammation, infection, regeneration all require energy.
| Intervention | Detail | Rationale |
|---|---|---|
| Caloric intake | 35–40 kcal/kg/day | Malnourished patients need aggressive caloric supplementation |
| Protein intake | 1.2–1.5 g/kg/day | Protein is essential for hepatocyte regeneration; do NOT restrict protein in HE — this is an outdated practice (see HE management) |
| Enteral feeding | Fine-bore nasogastric tube may be needed in severely ill patients [39] | Enteral feeding is ALWAYS first choice if GI tract can be used safely [41] — luminal nutrients reduce gut mucosal atrophy and decrease bacterial translocation |
| Specialised formula | Aminoleban: ↑ branched-chain amino acids (BCAA), for chronic liver disease patients [41] | BCAAs (leucine, isoleucine, valine) are preferentially metabolised by muscle, sparing the liver; aromatic amino acids (which worsen HE) are relatively reduced |
| Vitamin/trace mineral supplementation | Vitamins A, D, B1 (thiamine), B6 (pyridoxine), B9 (folate), zinc [2] | Folate deficiency → megaloblastic anaemia; B1 deficiency → Wernicke's; B6 deficiency → contributes to AST > ALT pattern; Zinc deficiency → impaired urea cycle (worsens HE), impaired taste |
| Thiamine (Vitamin B1) | High dose IV thiamine 500 mg Q8h × 2 days for Wernicke's encephalopathy [42]; then oral maintenance | Must be given before glucose; prophylactically to all admitted alcoholics |
Don't Restrict Protein in Hepatic Encephalopathy
An old teaching was to restrict dietary protein in patients with hepatic encephalopathy. This is wrong and has been abandoned. Protein restriction worsens malnutrition, accelerates muscle wasting (sarcopenia), and paradoxically worsens HE (because muscle is the main extra-hepatic site of ammonia metabolism — less muscle = more ammonia). Current guidelines recommend maintaining protein intake at 1.2–1.5 g/kg/day even in HE.
Pillar 3: Pharmacotherapy for Alcoholic Hepatitis
A. Corticosteroids — The Key Drug
Corticosteroids are indicated in patients with severe alcoholic hepatitis defined as having a Maddrey discriminant function (DF) ≥ 32 (OR) MELD score > 20 [39].
Objective assessment score is required to determine whether steroid therapy is beneficial since steroid can induce higher risk of infection — do NOT give steroids to every patient with alcoholic hepatitis [39].
The rationale for corticosteroids is pathophysiological: in severe AH, there is an overwhelming inflammatory cascade driven by TNF-α, IL-1β, IL-6, and IL-8 from Kupffer cells. Corticosteroids suppress this inflammation by:
- Inhibiting NF-κB → ↓ transcription of pro-inflammatory cytokines.
- ↓ Neutrophil chemotaxis → ↓ lobular inflammation.
- ↓ Kupffer cell activation.
- Stabilising hepatocyte membranes.
| Step | Detail |
|---|---|
| Drug and dose | Prednisolone 40 mg/day orally (or IV methylprednisolone if unable to take PO) |
| Duration | 28 days, then taper over 2 weeks (typically: stop at day 28 or taper from 40→30→20→10→0 over weeks 5–6) |
| Assessment of response | Day 7: calculate Lille score |
| Lille ≤ 0.45 | Steroid responder → complete 28-day course |
| Lille > 0.45 | Non-responder → stop steroids (continuing exposes patient to infection risk without benefit) [39] |
Why prednisolone and not prednisone? Prednisone is a prodrug that requires hepatic conversion to prednisolone (the active form). In severe liver disease, this conversion is impaired. Therefore, prednisolone is preferred.
Contraindications include sepsis, active GI bleeding, renal failure, or pancreatitis [39]:
| Contraindication | Reasoning |
|---|---|
| Active sepsis / uncontrolled infection | Steroids are immunosuppressive → will worsen infection → increased mortality. Must rule out and treat infection first (especially SBP). |
| Active GI bleeding | Steroids impair wound healing, increase ulcer risk, and can worsen haemostasis. |
| Renal failure / hepatorenal syndrome | Poor prognosis regardless; steroids do not improve outcomes in this subset. |
| Acute pancreatitis | Common in alcoholics; steroids can worsen pancreatitis. |
| Uncontrolled diabetes | Relative; steroids worsen glycaemic control — monitor closely if proceeding. |
The STOPAH Trial — What the Evidence Shows
The landmark STOPAH trial (2015, NEJM) — the largest RCT on alcoholic hepatitis treatment — showed:
- Prednisolone reduced 28-day mortality (trend, p=0.06) but NOT 90-day or 1-year mortality.
- Pentoxifylline showed no benefit at any time point.
- Combination (prednisolone + pentoxifylline) was no better than prednisolone alone.
The current consensus (ACG 2024, EASL 2024): prednisolone remains the standard of care for severe AH (mDF ≥ 32), but its benefit is modest and limited to the short term. The Lille score is essential for identifying non-responders early.
Pentoxifylline: a weak TNF inhibitor [39][32]:
- Reduces inpatient mortality, particularly from hepatorenal failure, in patients with severe alcoholic hepatitis [39].
- Mechanism: inhibits phosphodiesterase → ↑ cAMP → ↓ TNF-α production.
- However, the STOPAH trial showed no significant benefit → pentoxifylline has fallen out of favour in most guidelines.
- Monoclonal antibodies that neutralise serum TNF-α (e.g., infliximab) should NOT be used in alcoholic hepatitis due to increased death secondary to infection or renal failure [39].
The key teaching point: anti-TNF biologics (infliximab, etanercept) are harmful in AH despite the pathophysiology being TNF-driven. This is because complete TNF blockade cripples the immune system → overwhelming sepsis. Pentoxifylline's partial, non-specific anti-TNF effect was thought to be safer, but even that has not shown convincing benefit.
| Agent | Status | Mechanism |
|---|---|---|
| N-acetylcysteine (NAC) | Used as adjunct to prednisolone (AASLD recommends considering) | Replenishes glutathione → ↓ oxidative stress; some evidence of ↓ 1-month mortality when combined with steroids |
| G-CSF | Experimental [43] | Granulocyte colony-stimulating factor → stimulates hepatic progenitor cells → promotes liver regeneration |
| High volume plasma exchange | Emerging evidence [43] | Removes circulating cytokines and DAMPs causing systemic inflammation; very expensive but useful as combination treatment [43] |
| Liver support systems (MARS) | Experimental [43] | Molecular adsorbents recirculating system; albumin dialysis to remove toxins; not proven in AH |
| IL-22 agonists | Phase II trials | Promotes hepatocyte regeneration and protects against oxidative stress |
| FMT (faecal microbiota transplant) | Early clinical trials | Restores gut microbiome; reduces endotoxin translocation; promising early results |
Once a patient has progressed to alcoholic cirrhosis, the management shifts to complication prevention and treatment. This is identical to cirrhosis management of any aetiology but with the added imperative of alcohol abstinence.
| Complication | Management Approach |
|---|---|
| Ascites | Salt restriction (< 2 g/day Na); diuretics (spironolactone ± furosemide — start spironolactone 100 mg + furosemide 40 mg, titrate in 100:40 ratio); therapeutic paracentesis with albumin replacement (6–8 g albumin per litre drained if > 5L); TIPS for refractory ascites |
| SBP | Empiric IV cefotaxime (or ceftriaxone) when ascitic fluid PMN ≥ 250/mm³; IV albumin day 1 and day 3 to prevent HRS; secondary prophylaxis with oral norfloxacin or co-trimoxazole |
| Variceal bleeding | Acute: IV terlipressin (or octreotide) + IV PPI + emergent OGD with band ligation; transfuse to Hb target ~7–8 g/dL (over-transfusion worsens portal pressure). Primary prophylaxis: non-selective beta-blocker (propranolol or carvedilol) or band ligation. Secondary prophylaxis: NSBB + band ligation ± TIPS if refractory. |
| Hepatic encephalopathy | Identify and treat precipitant (infection, GI bleed, constipation, electrolyte imbalance, drugs); lactulose (titrate to 2–3 soft stools/day — converts NH₃ to NH₄⁺ in gut lumen, which cannot be absorbed); rifaximin (non-absorbable antibiotic ↓ ammonia-producing gut bacteria) for secondary prophylaxis |
| Hepatorenal syndrome | IV albumin + terlipressin (or noradrenaline in ICU); stop diuretics and nephrotoxins; ultimate treatment is liver transplantation |
| HCC surveillance | AFP + USS liver every 6 months [17] — indicated in all cirrhotics regardless of aetiology. For ALD/MASLD-related HCC, cirrhosis is a requirement for surveillance indication (unlike HBV where HCC can occur without cirrhosis) [17]. |
| Coagulopathy | IV vitamin K 10 mg if cholestatic component; FFP / platelets only before invasive procedures or active bleeding (NOT to "normalise" INR routinely) [44] |
| Nutritional support | As per Pillar 2 above |
Pillar 5: Liver Transplantation
Liver transplantation is an accepted indication for treatment in selected patients with alcoholic cirrhosis [39].
Liver transplantation is the final line — after exhausting all other treatments [43].
- End-stage alcoholic liver disease with hepatic decompensation (Child C cirrhosis, MELD ≥ 15).
- Unresectable HCC meeting Milan/UCSF criteria in the setting of alcoholic cirrhosis.
- Selected patients with severe alcoholic hepatitis non-responsive to medical therapy — this was previously controversial but increasingly accepted (see below).
Most centres require 6 months of abstinence before consideration for liver transplantation [2]:
- Rationale: identify patients at risk for relapse + allow time for liver recovery from ongoing alcohol-related injury [2].
- Monitor alcohol use using urine testing [2].
- 10–30% will have alcohol relapse after transplantation [2].
- Alcohol relapse is associated with graft rejection, recurrent ALD (usually rapidly progressive and may be fatal) [2].
The 6-month rule is practical rather than evidence-based. Some patients with severe AH who are steroid non-responders may die within 6 months if not transplanted. Emerging data (the Franco-Belgian trial, 2011) showed that early liver transplant in highly selected patients with severe AH (first episode, strong psychosocial support, no prior liver disease awareness) had 77% 6-month survival vs 23% without transplant. This has led to cautious relaxation of the 6-month rule in some centres, though it remains the standard in HK.
- Active alcohol / substance abuse (the 6-month rule)
- Active uncontrolled extrahepatic infection (e.g., HIV with uncontrolled viraemia)
- Extrahepatic malignancy
- Severe uncontrolled multisystem organ failure
- Inability to comply with transplant medications
- Inadequate psychosocial support
| Criteria | Detail |
|---|---|
| Milan criteria | Single lesion ≤ 5 cm OR ≤ 3 lesions each ≤ 3 cm; no gross vascular invasion; no nodal or distant metastasis [45] — > 75% 5-year survival |
| UCSF criteria | Single lesion ≤ 6.5 cm OR ≤ 3 lesions each ≤ 4.5 cm, total diameter sum ≤ 8 cm [45] — used as drop-off criteria |
| MELD score | Cr, bilirubin, INR (± Na) — used to prioritise the transplant list [5][45] |
Liver transplantation prognosis: 66–72% 5-year survival (23% if no liver transplant) [2].
Liver transplantation is NOT performed for patients with active alcoholic hepatitis due to increased surgical mortality and high rates of recidivism [39] — though this is evolving as above.
ALD-Specific Post-Transplant Considerations
- Immunosuppression protocol is standard (tacrolimus/ciclosporin + MMF ± steroids).
- Recurrence of ALD: 10–30% relapse; recurrent ALD on the graft is usually rapidly progressive and may be fatal.
- HBV carriers receiving transplant for non-HBV ALD: still need HBV prophylaxis (antivirals + HBIG if HBsAg positive) [45].
- Metabolic syndrome risk: immunosuppressive agents (steroids, tacrolimus) worsen hypertension, diabetes, hyperlipidaemia, and osteoporosis — compounding the alcoholic patient's pre-existing metabolic risk.
ACLF is defined as: acute liver insult manifesting jaundice and INR > 1.5, complicated within 4 weeks by ascites and/or encephalopathy, in patients with underlying chronic liver disease [43].
Alcoholic hepatitis is the most common cause of ACLF outside of Asia (in Asia, HBV reactivation is more common) [43].
ACLF has a much greater mortality → 28-day mortality > 20% [43].
Management principles [43]:
- Supportive — standard ICU care
- Identifying and removing/treating the insult (alcohol cessation)
- Manage complications (HE, renal failure, sepsis, coagulopathy)
- High volume plasma exchange — proven treatment; washes away cytokines causing liver failure; expensive but useful as combination treatment [43]
- Liver transplantation — the final line
| Stage | Key Interventions |
|---|---|
| Alcoholic Fatty Liver | Abstinence (reverses fully within weeks-months); nutritional counselling; address metabolic comorbidities; no pharmacotherapy needed |
| Mild-Moderate Alcoholic Hepatitis (mDF < 32) | Abstinence; nutritional support (35-40 kcal/kg/day, 1.2-1.5 g/kg/day protein); thiamine and multivitamins; manage withdrawal; supportive care |
| Severe Alcoholic Hepatitis (mDF ≥ 32) | All of the above PLUS prednisolone 40 mg/day × 28 days (if no contraindications); Lille score at day 7; stop steroids if non-responder (Lille > 0.45); consider NAC as adjunct; consider early liver transplant in highly selected steroid non-responders |
| Alcoholic Cirrhosis — Compensated | Abstinence; nutrition; variceal screening (OGD); HCC surveillance (AFP + USS 6-monthly); manage comorbidities |
| Alcoholic Cirrhosis — Decompensated | All of the above PLUS manage ascites, SBP, variceal bleeding, HE, HRS; assess for liver transplantation (6-month rule); calculate MELD for transplant prioritisation |
High Yield Summary
-
Alcohol abstinence is the cornerstone at every stage — reverses steatosis completely, slows fibrosis, reduces portal pressure, improves survival even in established cirrhosis.
-
Corticosteroids (prednisolone 40 mg/day × 28 days) are indicated when mDF ≥ 32 or MELD > 20 — do NOT give steroids to every patient with alcoholic hepatitis.
-
Contraindications to steroids: sepsis, active GI bleeding, renal failure, pancreatitis.
-
Lille score at day 7: ≤ 0.45 = responder (complete course); > 0.45 = non-responder (stop steroids).
-
Pentoxifylline has fallen out of favour (STOPAH trial showed no benefit); anti-TNF biologics (infliximab) are harmful.
-
Nutritional support is critical — 35-40 kcal/kg/day, 1.2-1.5 g/kg/day protein; do NOT restrict protein in HE.
-
Always give thiamine BEFORE glucose in alcoholic patients to prevent Wernicke's encephalopathy.
-
Manage alcohol withdrawal proactively — long-acting BDZs (diazepam/chlordiazepoxide); use oxazepam if severe liver disease; CIWA-Ar scale guides dosing.
-
Liver transplantation: 6-month abstinence rule; contraindicated in active alcohol use; 66-72% 5-year survival.
-
Milan criteria for HCC in transplant: single ≤ 5 cm or ≤ 3 each ≤ 3 cm, no vascular invasion, no metastasis.
Active Recall - Management of Alcoholic Liver Disease
References
[2] Senior notes: Ryan Ho GI, p.307 (alcohol abstinence outcomes, nutritional therapy, liver transplantation, 6-month rule, prognosis) [5] Senior notes: Block A - Gastrointestinal Data Interpretation, p.5 (Child-Pugh/MELD, transplant prioritisation) [17] Senior notes: Block A - Gastroenterology Interactive Tutorial, p.2 (HCC surveillance, FibroScan thresholds) [32] Senior notes: Maksim Medicine Notes, p.147 (CAGE, mDF, treatment of ALD, safety limits) [33] Senior notes: Ryan Ho Psychiatry, p.106 (alcohol withdrawal management, BDZs, CIWA-Ar, SADQ, prophylaxis) [39] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p.782–784 (treatment approach, corticosteroids, contraindications, pentoxifylline, liver transplantation) [40] Senior notes: Block A - Jaundice after raw oysters: acute hepatitis, p.3 (no alcohol for life, no drugs hasten recovery) [41] Senior notes: Ryan Ho Fluids and Nutrition, p.9 (enteral feeding, Aminoleban, specialised formulae) [42] Senior notes: Maksim Medicine Notes, p.148 (Wernicke's encephalopathy management, thiamine dosing) [43] Senior notes: Block A - A jaundiced and incoherent patient: liver failure, p.4, p.24 (ACLF definition, management principles, high volume plasma exchange, liver transplantation) [44] Senior notes: Maksim Medicine Notes, p.135 (liver failure management, coagulopathy, contraindications to transplant) [45] Senior notes: Maksim Surgery Notes, p.126–127 (liver transplantation criteria, Milan, UCSF, MELD, contraindications)
Complications of Alcoholic Liver Disease
Complications of ALD arise from two fundamental pathological processes that develop as the disease progresses:
- Hepatic insufficiency — the liver can no longer perform its synthetic, metabolic, and detoxification functions.
- Portal hypertension — fibrosis and architectural distortion increase intrahepatic resistance, raising pressure in the portal venous system.
Additionally, alcohol itself exerts direct toxic effects on other organ systems beyond the liver, producing a range of extra-hepatic complications unique to ALD.
The six associated complications of liver failure are: [46]
- Infections
- Variceal bleeding
- Ascites / Spontaneous bacterial peritonitis (SBP)
- Hepatorenal syndrome
- Hepatic encephalopathy
- (Coagulopathy)
- (Hepatocellular carcinoma → a complication you must ask for during history for any patient with cirrhosis) [46]
The one-slide overview of cirrhotic complications distinguishes compensated (Child A) from decompensated (Child B/C): [47]
| Compensated (Child A) | Decompensated (Child B/C) |
|---|---|
| Variceal disease | Variceal disease |
| Portal vein thrombosis | Portal vein thrombosis |
| HCC | Ascites |
| SBP | |
| Hepatic hydrothorax | |
| Hepatorenal syndrome | |
| Other: Infections, Bleeding tendency | Other: HE, HCC, Liver failure, Infections, Bleeding tendency |
ALD has additional concomitant presentations [48]:
- Other organ involvement: Psychiatric / CNS / Cardiac / Pancreatic / others
- Poor nutritional status
- Alcohol withdrawal (Day 2+ onward) — Delirium tremens
- Infections
- Cirrhotic complications: Variceal bleeding / Ascites / SBP / HE etc.
Complication 1: Portal Hypertension and Variceal Bleeding
In the normal liver, blood flows freely through sinusoids from the portal vein to the hepatic veins. In ALD-related cirrhosis:
- Structural component (75%): Fibrosis, regenerative nodules, and collagen deposition in the space of Disse → increased intrahepatic vascular resistance. The sinusoids lose their fenestrations ("capillarisation"), and pericellular fibrosis compresses them.
- Dynamic component (25%): Activated stellate cells and sinusoidal endothelial dysfunction → increased intrahepatic vasoconstrictor tone (↑endothelin, ↓nitric oxide production within the liver). Paradoxically, there is splanchnic vasodilatation (↑nitric oxide production in splanchnic circulation) → increased portal venous inflow.
The result: Portal venous pressure rises. When the hepatic venous pressure gradient (HVPG) exceeds 5 mmHg, portal hypertension exists. When it exceeds 10 mmHg, varices begin to form. When it exceeds 12 mmHg, variceal bleeding risk becomes significant.
The body attempts to decompress the portal system by shunting blood through collateral pathways:
| Collateral Site | Clinical Manifestation |
|---|---|
| Oesophageal and gastric veins | Oesophageal/gastric varices — most clinically significant; risk of catastrophic bleeding |
| Paraumbilical veins | Caput medusae — dilated periumbilical veins radiating from umbilicus |
| Rectal veins | Rectal varices (distinct from haemorrhoids) |
| Retroperitoneal veins | Usually not clinically apparent |
| Left renal vein (splenorenal shunt) | Spontaneous shunting; may worsen HE |
| Phase | Key Interventions |
|---|---|
| Primary prophylaxis | OGD screening Q2–3y in cirrhotics [49]; if medium/large varices → NSBB (propranolol/carvedilol) or endoscopic band ligation (EBL) |
| Acute variceal bleed | Resuscitate (target Hb 7–8 g/dL — over-transfusion increases portal pressure); IV terlipressin or octreotide (splanchnic vasoconstrictors); IV broad-spectrum antibiotics (ceftriaxone — infection worsens variceal bleeding); emergent OGD with EBL within 12h; TIPS for refractory bleeding |
| Secondary prophylaxis | Combination NSBB + EBL; TIPS if refractory |
50% of patients with alcoholic cirrhosis will develop cirrhotic complications, with 5-year transplant-free survival of only 60% in abstinence and 30% in drinkers [2].
Complication 2: Ascites
Ascites is the most common decompensating event in cirrhosis. The mechanism is a cascade:
- Portal hypertension → splanchnic vasodilatation (↑NO in mesenteric vessels) → ↓effective arterial blood volume.
- Effective hypovolaemia activates:
- RAAS (renin-angiotensin-aldosterone system) → sodium and water retention.
- Sympathetic nervous system → renal vasoconstriction → ↓GFR.
- ADH (vasopressin) → free water retention → dilutional hyponatraemia.
- Hypoalbuminaemia (impaired hepatic synthesis) → ↓oncotic pressure → fluid shifts from intravascular to interstitial/peritoneal space.
- Portal hypertension increases hydrostatic pressure in splanchnic capillaries → fluid transudation into peritoneal cavity.
The combination of these forces produces a transudative ascites with a SAAG (serum-ascites albumin gradient) ≥ 11 g/L — pathognomonic of portal hypertensive ascites.
| Step | Detail |
|---|---|
| Salt restriction | < 2 g Na/day (< 88 mmol/day); the most important dietary measure |
| Diuretics | Spironolactone (aldosterone antagonist) 100 mg + furosemide 40 mg; titrate in 100:40 ratio up to max spironolactone 400 mg + furosemide 160 mg; monitor weight (target loss 0.5 kg/day without oedema, 1 kg/day with oedema), electrolytes, and renal function |
| Therapeutic paracentesis | For tense ascites; give IV albumin (6–8 g per litre drained if > 5 L removed) to prevent post-paracentesis circulatory dysfunction |
| TIPS | For refractory ascites (defined as unresponsive to max diuretics or diuretic-intolerant); creates portosystemic shunt → ↓portal pressure |
| Liver transplantation | Definitive treatment for refractory ascites |
Cirrhotic complications listed in the one-slide overview include ascites [47]. Protein calorie malnutrition may increase risk of major complications including infection, HE, ascites [2].
Complication 3: Spontaneous Bacterial Peritonitis (SBP)
SBP is a bacterial infection of ascitic fluid without an identifiable intra-abdominal source of infection (no perforation, no abscess). The mechanism involves the gut-liver axis:
- Cirrhosis → intestinal bacterial overgrowth + ↑intestinal permeability ("leaky gut").
- Bacterial translocation → Gram-negative organisms (E. coli, Klebsiella) cross the gut wall into mesenteric lymph nodes and then into the bloodstream (bacteraemia) and ascitic fluid.
- The cirrhotic patient has impaired immune defences: ↓complement and opsonin levels in ascitic fluid (especially when ascitic protein < 10–15 g/L), reticuloendothelial dysfunction, ↓neutrophil function.
SBP requires high clinical suspicion [5]. May actually not have a lot of abdominal signs, since no perforation [5]. Culture is not useful (usually negative) → defined by checking the neutrophils [5].
- Diagnostic paracentesis in any cirrhotic with new/worsening ascites, fever, abdominal pain, encephalopathy, or unexplained clinical deterioration.
- SBP is diagnosed by ascitic fluid PMN ≥ 250/mm³, regardless of culture result [5].
- Ascitic fluid should also be sent for: albumin (SAAG), total protein, glucose, LDH, Gram stain, culture (inoculate into blood culture bottles at bedside to improve yield).
| Phase | Treatment |
|---|---|
| Empiric antibiotics | IV cefotaxime 2 g Q8h (or ceftriaxone 2 g daily) × 5–7 days; alternatives: co-amoxiclav, fluoroquinolones |
| IV albumin | 1.5 g/kg on day 1, 1 g/kg on day 3 — prevents hepatorenal syndrome (expands plasma volume, counteracts splanchnic vasodilatation) |
| Secondary prophylaxis | Long-term oral norfloxacin 400 mg daily or co-trimoxazole (to prevent recurrence — 70% recurrence at 1 year without prophylaxis) |
| Primary prophylaxis | Consider in patients with ascitic protein < 15 g/L or previous episode of SBP |
Infections in liver failure are very common [46]. Bacteria, especially from the respiratory and urinary tract (Staph, Strep, Gram-negative rods). Bacteraemia in up to 25% of fulminant hepatic failure patients. Fungal infection, especially Candida, but bacterial still most common [46].
The mechanism behind why liver failure patients are susceptible to infection: reticuloendothelial dysfunction and reduced opsonisation — the liver cannot clear toxins, and production of complement/opsonins is impaired [46].
Complication 4: Hepatic Encephalopathy (HE)
HE is a spectrum of neuropsychiatric abnormalities in patients with liver failure/portal hypertension, caused by accumulation of neurotoxins (principally ammonia) that the liver can no longer metabolise.
- Ammonia source: Produced by bacterial urease in the gut (40%) and directly from dietary protein breakdown (60%).
- Normal clearance: Ammonia is converted to urea by the hepatic urea cycle → excreted by kidneys. In liver failure, this cycle is impaired. Portal-systemic shunting also diverts ammonia-rich portal blood away from the liver.
- Neurotoxicity: Ammonia crosses the blood-brain barrier → astrocytes convert it to glutamine (via glutamine synthetase) → glutamine is osmotically active → astrocyte swelling → cerebral oedema (mainly in acute liver failure); also disrupts neurotransmission (↑GABAergic tone, ↓glutamatergic tone).
- Other neurotoxins: Manganese (deposits in basal ganglia), mercaptans (fetor hepaticus), short-chain fatty acids, and inflammatory cytokines all contribute.
| Grade | West Haven Criteria |
|---|---|
| Minimal (covert) | Abnormal psychometric tests only; clinically undetectable |
| Grade 1 | Shortened attention span, euphoria/anxiety, impaired calculation |
| Grade 2 | Lethargy, disorientation to time, personality change, asterixis |
| Grade 3 | Somnolence, marked confusion, disorientation to place, bizarre behaviour |
| Grade 4 | Coma |
Hepatic encephalopathy is a diagnosis of exclusion [29]:
- Arterial ammonia: not always raised, may not correlate with severity; not diagnostic [29].
- EEG abnormalities: for patients where diagnosis is difficult or in ICU [29].
- Psychometric tests: constructional apraxia (drawing a 5-point star), Reitan's test (number connection) [29].
- Other clinical features: fetor hepaticus, flapping tremor (asterixis) [29].
Confusion in cirrhosis does NOT mean HE. HE is a less common cause of confusion in cirrhosis — confusion is still most commonly caused by head injury and drug-related causes [29].
| Step | Detail | Mechanism |
|---|---|---|
| Identify and treat precipitant | GI bleed (↑ammonia from blood protein digestion); infection/SBP; constipation; electrolyte imbalance (hypokalaemia → metabolic alkalosis → ↑renal NH₃ production + ↑diffusion across BBB); sedatives/opioids; dehydration | Removing the trigger is often sufficient to reverse HE |
| Lactulose | 15–30 mL Q6–8h; titrate to 2–3 soft stools/day | Non-absorbable disaccharide → colonic bacteria ferment it to lactic acid → ↓intraluminal pH → converts NH₃ (absorbable) to NH₄⁺ (non-absorbable, trapped in gut lumen) → excreted in stool; also acts as osmotic laxative, ↓colonic transit time |
| Rifaximin | 550 mg BD (secondary prophylaxis) | Non-absorbable antibiotic → ↓ammonia-producing gut bacteria; well tolerated; reduces recurrence of HE by ~50% |
| Nutritional support | Maintain protein 1.2–1.5 g/kg/day; BCAA supplements (Aminoleban) | Do NOT restrict protein; BCAAs preferentially metabolised by muscle, sparing the liver |
Complication 5: Hepatorenal Syndrome (HRS)
HRS is not primary kidney disease — the kidneys are structurally normal. It is a functional renal failure caused by extreme splanchnic vasodilatation in advanced cirrhosis:
- Progressive splanchnic vasodilatation → ↓↓ effective arterial blood volume.
- Maximal compensatory activation of RAAS, SNS, and ADH cannot maintain renal perfusion.
- Intense renal vasoconstriction → ↓↓GFR → oliguric renal failure.
- If you transplant the liver, the kidneys recover — proving the problem was haemodynamic, not structural.
| Type | Features | Prognosis |
|---|---|---|
| HRS-AKI (formerly Type 1) | Rapidly progressive; doubling of creatinine to > 221 μmol/L within 2 weeks; often precipitated by SBP, GI bleed, or large-volume paracentesis without albumin | Very poor; median survival ~2 weeks without treatment |
| HRS-CKD (formerly Type 2) | Moderate, slowly progressive renal impairment; often associated with refractory ascites | Better than Type 1 but still poor |
- No structural kidney disease (normal renal USS).
- No response to 48-hour plasma volume expansion with IV albumin (1 g/kg/day, max 100 g/day).
- No shock, nephrotoxic drugs, or significant proteinuria.
- Urine sodium < 10 mmol/L (kidneys avidly retaining sodium — "pre-renal" physiology).
| Treatment | Detail |
|---|---|
| IV albumin + terlipressin | First-line for HRS-AKI; terlipressin is a vasopressin analogue → splanchnic vasoconstriction → ↑effective arterial volume → ↑renal perfusion; albumin expands plasma volume. Alternative: noradrenaline in ICU. |
| Stop diuretics and nephrotoxins | Remove any iatrogenic contribution |
| TIPS | May improve renal function by ↓portal pressure |
| Liver transplantation | Definitive treatment; kidneys recover post-transplant |
| Renal replacement therapy | Bridge to transplant only; not a long-term solution |
Complication 6: Coagulopathy
The liver synthesises essentially all clotting factors (except vWF and factor VIII, which are made by endothelial cells) and the natural anticoagulants (protein C, protein S, antithrombin). In liver failure:
- ↓ Pro-coagulant factors (II, V, VII, IX, X, XI, fibrinogen) → ↑ bleeding tendency.
- ↓ Anti-coagulant factors (protein C, protein S, antithrombin) → ↑ thrombotic tendency.
- ↓ Fibrinolytic factors (plasminogen) but also ↓ antifibrinolytics (α2-antiplasmin, TAFI).
This creates a "rebalanced haemostasis" — the INR looks terrible, but the patient is not necessarily bleeding because the loss of anticoagulants partially compensates. In fact, cirrhotic patients can develop thrombotic complications (portal vein thrombosis, DVT).
Factor VII has the shortest half-life (6 hours) → PT/INR is the first clotting parameter to become abnormal in liver failure [11].
- Thrombocytopenia from hypersplenism (portal hypertension → congestive splenomegaly → platelet sequestration) and ↓hepatic thrombopoietin production.
- Dysfibrinogenaemia — qualitatively abnormal fibrinogen.
- DIC — may be triggered by sepsis or severe AH.
- Vitamin K deficiency — impaired bile salt production → impaired fat-soluble vitamin absorption (K-dependent factors: II, VII, IX, X). Distinguish from true synthetic failure: give IV vitamin K 10 mg × 3 days; if PT corrects → cholestatic cause; if PT does not correct → hepatocellular failure [35].
Complication 7: Hepatocellular Carcinoma (HCC)
HCC is a complication you must ask for during history for any patient with cirrhosis [46].
- Cirrhosis itself is the strongest risk factor — the chronic cycle of hepatocyte death → regeneration → DNA replication errors → dysplastic nodules → HCC.
- Alcohol-specific carcinogenesis: Acetaldehyde is a carcinogen (forms DNA adducts); CYP2E1-generated ROS cause oxidative DNA damage; chronic inflammation promotes a tumour-permissive microenvironment.
- 100% of patients with HCV infection or alcoholic liver disease who develop HCC have underlying liver cirrhosis [50][51] — unlike HBV, where HCC can occur without cirrhosis due to viral DNA integration. This means that for ALD-related HCC, cirrhosis is a requirement for HCC surveillance indication [17].
- Present in the late stage — asymptomatic when tumour < 8 cm; NO nerve fibres in the liver.
- Majority have underlying liver cirrhosis (80–100%) → limits scope for resection.
- Early venous permeation → high recurrence rate.
- Field cancerisation effect → whole liver is exposed to oncogenic influence.
Complication 8: Extra-Hepatic Complications of Chronic Alcoholism
These are complications related to alcohol itself rather than liver failure, though they frequently coexist with ALD. They are crucial in the holistic management of the ALD patient.
ALD has concomitant presentations: other organ involvement — Psychiatric / CNS / Cardiac / Pancreatic / others [48].
| Complication | Pathogenesis | Clinical Features | Management |
|---|---|---|---|
| Wernicke's encephalopathy | Thiamine (B1) deficiency → haemorrhage in periventricular grey matter [42] | Classical triad only in 15–30% of patients: confusion, ataxia, ophthalmoplegia; difficult to differentiate from acute intoxication [42] | High dose IV thiamine 500 mg Q8h × 2 days; correct hypomagnesaemia (Mg is cofactor for thiamine); closely monitor BP/pulse [42] |
| Korsakoff's syndrome | 80% of untreated Wernicke's progress to this [42] | Irreversible anterograde amnesia, confabulation | Long-term oral thiamine; largely irreversible |
| Alcoholic peripheral neuropathy | Direct neurotoxicity + B1/B12 deficiency → Wallerian degeneration | Stocking-glove sensory loss, painful paraesthesia, weakness | Abstinence; thiamine and B12 supplementation |
| Alcoholic cerebellar degeneration | Nutritional deficiency + neurotoxicity → degeneration of Purkinje cells → vermis atrophy [52] | Subacute/chronic onset of ataxic gait, truncal ataxia; CT/MRI shows anterior vermis atrophy [52] | Abstinence; nutritional supplementation; stabilises with abstinence but progresses with continued drinking [52] |
| Marchiafava-Bignami disease | Demyelination of corpus callosum due to hypovitaminosis B [52] | Frontal dementia, personality changes, seizures, spasticity | Thiamine and B-vitamins; variable prognosis |
| Central pontine myelinolysis | Rapid correction of hyponatraemia (iatrogenic) | Quadriparesis, "locked-in" syndrome, dysarthria | Prevention: correct Na slowly (< 10 mmol/L in 24h) |
Other cardiovascular conditions associated with high alcohol content: [18]
- Coronary artery disease
- Atrial fibrillation → cardiac arrhythmias
- Alcoholic dilated cardiomyopathy (ACM) — direct ethanol toxicity to cardiomyocytes → LV dilatation, impaired contractility → heart failure [13]. Toxic aetiology of dilated cardiomyopathy [13]. Reversible with early abstinence.
- Hypertension
Alcohol is the major aetiology of chronic pancreatitis [14]:
- Chronic pancreatitis → exocrine insufficiency (steatorrhoea, malabsorption, fat-soluble vitamin deficiency) + endocrine insufficiency (diabetes mellitus).
- Pathological classification: calcifying pancreatitis — fibrosis with intraductal stones, associated with alcohol [14].
- Acute pancreatitis can also be precipitated by alcohol (though gallstones are the more common cause of acute pancreatitis).
Alcoholic hepatitis general management includes: assessing and managing pancreatitis [48].
| Complication | Mechanism |
|---|---|
| Macrocytic anaemia | Direct ethanol toxicity to RBC membranes + folate/B12 deficiency |
| Sideroblastic anaemia | Alcohol impairs haem synthesis → ring sideroblasts in marrow |
| Thrombocytopenia | Direct marrow suppression + hypersplenism |
| Neutropenia | Direct marrow suppression |
| Zieve's syndrome | Jaundice + hyperlipidaemia + haemolytic anaemia [7] |
| System | Complication | Mechanism |
|---|---|---|
| GI | Gastritis, Mallory-Weiss tear | Direct mucosal irritation; retching from nausea |
| GI | Oesophageal squamous cell carcinoma | Acetaldehyde is a local carcinogen (especially with ALDH2*2 + smoking synergy) |
| Metabolic | Hypoglycaemia | Ethanol inhibits gluconeogenesis (NADH/NAD⁺ imbalance) |
| Metabolic | Lactic acidosis | Type B lactic acidosis: reduced metabolism of L-lactate due to liver problems and alcoholism [53] |
| Metabolic | Alcoholic ketoacidosis | Starvation + dehydration + ethanol metabolism → ↑NADH → ↑β-hydroxybutyrate; treated with dextrose-saline (NOT insulin, unlike DKA) |
| Metabolic | Hypertriglyceridaemia | Impaired VLDL secretion + ↑hepatic lipogenesis [54] |
| Musculoskeletal | Proximal myopathy, rhabdomyolysis | Direct myotoxicity → type II fibre atrophy; acute binge → rhabdomyolysis |
| Skeletal | Osteoporosis | Alcohol suppresses osteoblasts; nutritional deficiency (calcium, vitamin D); hypogonadism |
| Reproductive | Hypogonadism, infertility | Direct gonadal toxicity + hyperestrogenism |
| Psychiatric | Alcohol use disorder, depression, anxiety, psychosis | Neurotransmitter dysregulation; social dysfunction |
| Fetal | Fetal alcohol spectrum disorder | Ethanol is teratogenic — facial dysmorphism, microcephaly, intellectual disability, growth restriction |
ACLF = acute liver insult manifesting as jaundice and INR > 1.5, complicated within 4 weeks by ascites and/or encephalopathy, in patients with underlying chronic liver disease [43].
Alcoholic hepatitis is the most common cause of ACLF in Western countries [43]. In HK and Asia, HBV-related ACLF is more common [43].
ACLF has a much greater mortality → 28-day mortality > 20% [43].
Prognostic factors for ACLF depend on 6 organ-specific factors: [46]
- Cerebral: HE
- Respiration: SaO₂/FiO₂
- Circulation: Need for vasopressor
- Liver: Bilirubin level
- Coagulation: INR level
- Kidney: Creatinine level
All 3 components of the MELD score are present in these 6 factors → MELD score is still useful in prognosticating ACLF [46].
| Complication | Pathophysiology | Key Points |
|---|---|---|
| Hepatic hydrothorax | Ascitic fluid tracks through diaphragmatic defects (usually right-sided) | Right-sided pleural effusion in a cirrhotic; transudative; managed like ascites (diuretics, salt restriction, TIPS); chest tube alone is insufficient and contraindicated (continuous fluid loss, infection risk) |
| Portal hypertensive gastropathy | Mucosal and submucosal congestion in stomach due to portal HTN | Endoscopically: "snakeskin" or mosaic pattern of gastric mucosa; chronic oozing → iron deficiency anaemia; managed with NSBB, iron supplementation |
| Hepatopulmonary syndrome | Intrapulmonary vascular dilatation → V/Q mismatch → hypoxaemia (worse on standing — platypnoea; improved on lying flat — orthodeoxyia) | Diagnosed by contrast echocardiography (microbubble test); treated by liver transplantation |
| Portopulmonary hypertension | Pulmonary arterial hypertension in the setting of portal HTN | Elevated mPAP > 25 mmHg at rest; screening by echo; confirmed by right heart catheterisation; treatment with pulmonary vasodilators; if mPAP > 35 mmHg → relative contraindication to liver transplant (peri-operative mortality) |
| Cirrhotic cardiomyopathy | Blunted contractile response to stress, diastolic dysfunction, QT prolongation | May become apparent post-TIPS or post-transplant (↑venous return unmasks poor contractile reserve) |
| Pathophysiology | Complications |
|---|---|
| Portal hypertension | Variceal bleeding, ascites, SBP, splenomegaly/hypersplenism, hepatic hydrothorax, portal hypertensive gastropathy, hepatopulmonary syndrome, portopulmonary hypertension |
| Hepatic insufficiency | Hepatic encephalopathy, coagulopathy, jaundice, hypoalbuminaemia, hypoglycaemia |
| Combined | Hepatorenal syndrome, ACLF, HCC |
| Direct alcohol toxicity (extra-hepatic) | Wernicke-Korsakoff, peripheral neuropathy, cerebellar degeneration, cardiomyopathy, pancreatitis, myopathy, osteoporosis, haematological disorders, psychiatric disorders, fetal alcohol spectrum disorder |
High Yield Summary
-
Six complications of liver failure: infections, variceal bleeding, ascites/SBP, hepatorenal syndrome, hepatic encephalopathy, coagulopathy — plus HCC.
-
Portal hypertension = structural (fibrosis, nodules) + dynamic (vasoconstrictor/vasodilator imbalance); HVPG > 12 mmHg → variceal bleeding risk.
-
SBP: diagnosed by ascitic fluid PMN ≥ 250/mm³ (NOT by culture); may have minimal abdominal signs; requires high clinical suspicion.
-
HE is a diagnosis of exclusion; ammonia is not diagnostic. Confusion in cirrhosis ≠ HE — head injury, drugs, withdrawal, infection are commoner.
-
HRS is functional renal failure (structurally normal kidneys); splanchnic vasodilatation → effective hypovolaemia → renal vasoconstriction; treated with albumin + terlipressin; cured by liver transplant.
-
100% of ALD patients with HCC have underlying cirrhosis → cirrhosis is required for HCC surveillance (6-monthly AFP + USS).
-
Coagulopathy in cirrhosis is "rebalanced" — both pro- and anti-coagulant factors are low; INR overestimates bleeding risk; thrombosis also occurs.
-
Extra-hepatic complications of alcohol (CNS/cardiac/pancreatic/psychiatric/nutritional) must be actively looked for in every ALD patient.
-
Wernicke's triad (confusion, ophthalmoplegia, ataxia) only present in 15-30% of cases; mortality 20%; 80% progress to irreversible Korsakoff's syndrome.
-
ALD-specific concomitant presentations include: psychiatric/CNS/cardiac/pancreatic involvement, poor nutritional status, and alcohol withdrawal (delirium tremens from Day 2+).
Active Recall - Complications of Alcoholic Liver Disease
References
[2] Senior notes: Ryan Ho GI, p.306–307 (alcoholic cirrhosis prognosis, nutritional therapy, complications) [5] Senior notes: Block A - Gastrointestinal Data Interpretation, p.5 (SBP diagnosis by neutrophils, high suspicion) [7] Lecture slides: GC 240. MASLD and Alcoholic Liver Disease.pdf, p.16 (Zieve's syndrome) [11] Senior notes: Block A - Jaundice after raw oysters: acute hepatitis, p.2 (PT/INR for prognosis monitoring) [13] Senior notes: Ryan Ho Cardiology, p.169 (dilated cardiomyopathy — alcoholic as toxic cause) [14] Senior notes: Block A - Upper abdominal pain: peptic ulcer; pancreatitis and gallstone, p.34 (chronic pancreatitis — alcoholic aetiology, calcifying type) [17] Senior notes: Block A - Gastroenterology Interactive Tutorial, p.2 (HCC surveillance, cirrhosis as requirement for ALD) [18] Senior notes: Block A - WCS32 Chest pain on exertion: ischaemic heart disease, p.11 (alcohol and CVS conditions) [29] Senior notes: Block A - A jaundiced and incoherent patient: liver failure, p.17 (confusion ≠ HE, HE diagnosis by exclusion, ammonia not diagnostic) [35] Senior notes: Block A - Abnormal bleeding after tooth extraction, p.10 (PT in liver disease, vitamin K test) [42] Senior notes: Maksim Medicine Notes, p.148 (Wernicke's encephalopathy — triad 15-30%, 80% → Korsakoff's, treatment) [43] Senior notes: Block A - A jaundiced and incoherent patient: liver failure, p.4, p.24 (ACLF definition, causes, management, high volume plasma exchange) [46] Senior notes: Block A - A jaundiced and incoherent patient: liver failure, p.12 (6 complications of liver failure, ACLF prognostic factors, infections in liver failure) [47] Lecture slides: GC 026. Abdominal distension_ascites and cirrhosis.pdf, p.34 (one-slide overview of cirrhotic complications) [48] Lecture slides: GC 240. MASLD and Alcoholic Liver Disease.pdf, p.15, p.19 (concomitant presentations, general management of AH) [49] Senior notes: Ryan Ho GI, p.315 (OGD screening Q2-3y, HCC surveillance Q6mo) [50] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p.840 (HCC prognosis, 100% ALD/HCV with cirrhosis, surveillance 6-monthly) [51] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai), p.496 (HCC prognosis, surveillance intervals) [52] Senior notes: Ryan Ho Psychiatry, p.109 (cerebellar degeneration, Marchiafava-Bignami disease) [53] Senior notes: Block A - Electrolyte and Acid-Base Disorders, p.7 (Type B lactic acidosis — liver, alcoholism) [54] Senior notes: Ryan Ho Endocrine, p.124 (hypertriglyceridaemia — hepatocellular disease and alcoholism)
High Yield Summary
-
ALD is a spectrum: Steatosis → Steatohepatitis → Fibrosis → Cirrhosis, with frequent overlap between stages.
-
Pathophysiology is multi-hit: NADH/NAD⁺ imbalance (→ steatosis), acetaldehyde toxicity (→ protein adducts, mitochondrial damage), CYP2E1-generated ROS (→ oxidative stress), gut-liver axis endotoxin (→ Kupffer cell activation, TNF-α), and stellate cell activation (→ fibrosis).
-
AST:ALT ratio ≥ 2:1 with AST < 400–500 U/L is the classic LFT pattern of alcoholic hepatitis — due to B6 deficiency reducing ALT and mitochondrial AST release.
-
GGT is disproportionately elevated (inducible enzyme) and MCV is raised (direct membrane toxicity) — both are clues to alcohol as the aetiology.
-
The 4 conditions where AST > ALT: Alcoholic hepatitis, HCC, congestive heart failure, ischaemic hepatitis.
-
Portal hypertension can develop in alcoholic hepatitis EVEN WITHOUT established cirrhosis — due to sinusoidal compression by swollen hepatocytes and perisinusoidal fibrosis.
-
Always exclude concomitant liver disease (HBV, HCV, autoimmune, metabolic) — especially in HK where HBV + alcohol + MASLD overlap is common.
-
Scoring: Maddrey DF ≥ 32 or MELD ≥ 21 = severe alcoholic hepatitis. Child-Pugh and MELD score cirrhosis severity. Lille score at day 7 assesses steroid response.
-
Extra-hepatic clues to chronic alcoholism: Parotid enlargement, Dupuytren's contracture, peripheral neuropathy, proximal myopathy, macrocytosis, cardiomyopathy, chronic pancreatitis, cerebellar degeneration.
-
Women are more susceptible to ALD at lower doses due to lower gastric ADH, higher body fat percentage, and estrogen-mediated gut permeability.
High Yield Summary
-
No single lab test reliably differentiates ALD from other liver diseases — diagnosis requires compatible history + exclusion of other causes.
-
AST:ALT > 2:1 with AST < 500, ↑GGT, ↑MCV = classic ALD pattern; but the 4 conditions with AST > ALT are: alcoholic hepatitis, HCC, CHF, ischaemic hepatitis.
-
Always exclude concomitant liver disease in HK: HBV, HCV, MASLD — dual/triple pathology is common.
-
Immunoglobulin pattern: ↑IgA = ALD; ↑IgG = AIH; ↑IgM = PBC.
-
Confusion in cirrhosis ≠ hepatic encephalopathy — head injury, drugs, withdrawal, infection, metabolic disturbance are commoner; HE is a diagnosis of exclusion.
-
Hepatomegaly in ALD: smooth, soft (fatty liver or alcoholic hepatitis) or smooth with nodules (cirrhosis) — contrast with hard, nodular (malignancy).
-
ANI score can help distinguish ALD from MASLD when history is unreliable (> 0 favours ALD, < 0 favours MASLD).
-
Liver biopsy may be required when diagnosis is unclear due to atypical features or possible concomitant disease — "only useful here" [8] for definitively distinguishing overlapping aetiologies.
High Yield Summary
-
ALD is a clinical diagnosis — compatible history + characteristic lab pattern + exclusion of other causes. No single test is pathognomonic.
-
The diagnostic lab triad of ALD: AST:ALT ≥ 2:1 (AST < 500), disproportionately ↑GGT, ↑MCV.
-
For alcoholic hepatitis, must exclude biliary obstruction (imaging) and other types of hepatitis — viral serology, autoimmune panel, metabolic screen, and drug history are mandatory.
-
Severity scoring: mDF ≥ 32 → severe AH → steroids. Lille score > 0.45 at day 7 → steroid non-responder → stop. MELD ≥ 21 → high mortality.
-
CAGE questionnaire (≥ 2 positive = positive screen) is the quick bedside screening tool for alcohol use disorder.
-
USS liver is first-line imaging — detects steatosis (hyperechoic), fibrosis (coarse echo), cirrhosis (nodular surface), and excludes biliary obstruction.
-
FibroScan: liver stiffness > 12 kPa suggests cirrhosis; CAP score > 280 dB/m suggests severe steatosis.
-
Liver biopsy is gold standard but reserved for diagnostic uncertainty — histological hallmarks are macrovesicular steatosis, ballooning, Mallory-Denk bodies, neutrophilic infiltrate, and perivenular fibrosis.
-
SBP is diagnosed by ascitic fluid PMN ≥ 250/mm³, not by culture (culture often negative).
-
Always check viral markers in a patient with ALD — concomitant HBV/HCV is common in HK and changes management.
High Yield Summary
-
Alcohol abstinence is the cornerstone at every stage — reverses steatosis completely, slows fibrosis, reduces portal pressure, improves survival even in established cirrhosis.
-
Corticosteroids (prednisolone 40 mg/day × 28 days) are indicated when mDF ≥ 32 or MELD > 20 — do NOT give steroids to every patient with alcoholic hepatitis.
-
Contraindications to steroids: sepsis, active GI bleeding, renal failure, pancreatitis.
-
Lille score at day 7: ≤ 0.45 = responder (complete course); > 0.45 = non-responder (stop steroids).
-
Pentoxifylline has fallen out of favour (STOPAH trial showed no benefit); anti-TNF biologics (infliximab) are harmful.
-
Nutritional support is critical — 35-40 kcal/kg/day, 1.2-1.5 g/kg/day protein; do NOT restrict protein in HE.
-
Always give thiamine BEFORE glucose in alcoholic patients to prevent Wernicke's encephalopathy.
-
Manage alcohol withdrawal proactively — long-acting BDZs (diazepam/chlordiazepoxide); use oxazepam if severe liver disease; CIWA-Ar scale guides dosing.
-
Liver transplantation: 6-month abstinence rule; contraindicated in active alcohol use; 66-72% 5-year survival.
-
Milan criteria for HCC in transplant: single ≤ 5 cm or ≤ 3 each ≤ 3 cm, no vascular invasion, no metastasis.
High Yield Summary
-
Six complications of liver failure: infections, variceal bleeding, ascites/SBP, hepatorenal syndrome, hepatic encephalopathy, coagulopathy — plus HCC.
-
Portal hypertension = structural (fibrosis, nodules) + dynamic (vasoconstrictor/vasodilator imbalance); HVPG > 12 mmHg → variceal bleeding risk.
-
SBP: diagnosed by ascitic fluid PMN ≥ 250/mm³ (NOT by culture); may have minimal abdominal signs; requires high clinical suspicion.
-
HE is a diagnosis of exclusion; ammonia is not diagnostic. Confusion in cirrhosis ≠ HE — head injury, drugs, withdrawal, infection are commoner.
-
HRS is functional renal failure (structurally normal kidneys); splanchnic vasodilatation → effective hypovolaemia → renal vasoconstriction; treated with albumin + terlipressin; cured by liver transplant.
-
100% of ALD patients with HCC have underlying cirrhosis → cirrhosis is required for HCC surveillance (6-monthly AFP + USS).
-
Coagulopathy in cirrhosis is "rebalanced" — both pro- and anti-coagulant factors are low; INR overestimates bleeding risk; thrombosis also occurs.
-
Extra-hepatic complications of alcohol (CNS/cardiac/pancreatic/psychiatric/nutritional) must be actively looked for in every ALD patient.
-
Wernicke's triad (confusion, ophthalmoplegia, ataxia) only present in 15-30% of cases; mortality 20%; 80% progress to irreversible Korsakoff's syndrome.
-
ALD-specific concomitant presentations include: psychiatric/CNS/cardiac/pancreatic involvement, poor nutritional status, and alcohol withdrawal (delirium tremens from Day 2+).